

09/601645

Date of Deposit: August 4, 2000

533 Rec'd PCT/PTO 04 AUG 2000


I hereby certify that this paper of fee and the papers indicated as being attached hereto are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 C.F.R. §1.10 on the date indicated above and are addressed to the Commissioner of Patents and Trademarks, BOX PCT Washington, D.C. 20231.

Kathy Holloway
(Typed or printed name of person mailing)

Kathy Holloway
(Signature of person mailing)

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. §371		ATTORNEY DOCKET NUMBER 24741-1509US
INTERNATIONAL APPLICATION NO. PCT/EP99/00716	INTERNATIONAL FILING DATE 03 February 1999	PRIORITY DATE CLAIMED 04 February 1998
TITLE: METHOD OF QUANTITATIVE DETERMINATION OF TUMOR CELLS IN A BODY FLUID AND TEST KITS SUITABLE THEREFOR		
APPLICANTS FOR DO/EO/US: Michael W. Dahm, Robert C. Phelps, Carsten Brockmeyer		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. §371.		
2. <input type="checkbox"/> This is a SECOND OR SUBSEQUENT submission of items concerning a filing under 35 U.S.C. §371.		
3. <input checked="" type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. §371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. §371(b) and PCT Articles 22 and 39(1).		
4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.		
5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. §371(c)(2)): a. <input checked="" type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).		
6. <input checked="" type="checkbox"/> A translation of the International Application into English (35 U.S.C. §371(c)(2)).		
7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. §371(c)(3)): a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input checked="" type="checkbox"/> have been transmitted by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made.		
8. <input checked="" type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. §371(c)(3)).		
9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. §371(c)(4)).		
10. <input checked="" type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. §371(c)(5)).		
Items 11 to 16 concern other documents or information included:		
11. <input type="checkbox"/> An Information Disclosure Statement under 37 C.F.R. §§1.97 and 1.98.		
12. <input checked="" type="checkbox"/> A DECLARATION and POWER OF ATTORNEY with claim under 35 U.S.C. §119 for benefit of priority application European Application Serial No. DE 198 04 372.4		
13. <input checked="" type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.		
14. <input type="checkbox"/> A substitute specification.		
15. <input type="checkbox"/> A change of power of attorney and/or address letter.		
16. <input checked="" type="checkbox"/> Other items of information: A SEQUENCE LISTING and DISK copy thereof.		

APPLICATION 09/60165	INTERNATIONAL APPLN. NO. PCT/EP99/00716	ATTORNEY DOCKET NUMBER 24741-1509US		
17. <input checked="" type="checkbox"/> The following fees are submitted:		CALCULATIONS PTO USE ONLY		
Basic National Fee (37 CFR 1.492(a)(1)-(5)): Search Report has been prepared by the EPO or JPO International preliminary examination fee paid to PTO (37 CFR 1.482) No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) Neither international preliminary examination fee paid to USPTO (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Articles 33(2)-(4)		\$ 840.00 \$ 670.00 \$ 760.00 \$ 970.00 \$ 96.00		
ENTER APPROPRIATE BASIC FEE AMOUNT =		\$ 840.00		
Surcharge of \$130.00 for furnishing the oath or declaration later than <input checked="" type="checkbox"/> 20 <input type="checkbox"/> 30 months for the earliest claimed priority date (37 CFR 1.492(e)).		\$ 130.00		
Claims*	Number Filed	Number Extra	Rate	
Total claims	68	48	18	\$ 864.00
Independent claims	2	0	78	\$ 0.00
Multiple dependent claims		0	230	\$ 0.00
BASED UPON ENTRY OF THE ATTACHED PRELIMINARY AMENDMENT		TOTAL OF ABOVE CALCULATIONS = \$1834.00		
Reduction by 1/2 for filing small entity		\$ 917.00		
		SUBTOTAL = \$ 917.00		
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months for the earliest claimed priority date (37 CFR 1.492(f)).				
		TOTAL NATIONAL FEE = \$1047.00		
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) \$40.00 per property.		\$ 0.00		
		TOTAL FEES ENCLOSED = \$1047.00		
		Amount to be: refunded		\$
		charged		\$
a. <input checked="" type="checkbox"/> A check in the amount of \$1047.00 to cover the above fees is enclosed. A duplicate of this sheet is enclosed. b. <input checked="" type="checkbox"/> Please charge Deposit Account No. 50-1213 for the above fees or for any amount due that is not covered by the enclosed check or if the enclosed check is in the wrong amount, post-dated or otherwise improper. A duplicate of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any other fees that may be required, or credit any overpayment to Deposit Account No. 50-1213 is enclosed.				
SEND ALL CORRESPONDENCE TO:				
Stephanie Seidman Heller Ehrman White & McAuliffe LLP 4250 Executive Square, 7th Floor La Jolla, CA 92037 Telephone: (858) 450-8400 Facsimile: (858) 587-5360				


 Stephanie Seidman

PRELIMINARY AMENDMENT

the label is selected from a radioactive label, a biotin label, a fluorescent label or an electrochemoluminescent label.—

—56. The method of Claim 9, wherein the label is a radioactive label, a biotin label, a fluorescent label or an electrochemoluminescent label.—

—57. The method of Claim 11, wherein, as a positive control in the sample, a nucleic acid that occurs in peripheral blood is specifically amplified and detected.—

—58. The method of Claim 57, wherein the nucleic acid is mRNA that encodes a protein selected from among β -globin, glyceraldehyde-phosphate dehydrogenase, β -actin or a T-cell receptor.—

—59. The method of Claim 3, wherein as a negative control no reverse transcription reaction is carried out before the amplification reaction with the sample to be investigated and/or water is employed in place of the body fluid.—

—60. The method of Claim 16, wherein depletion is effected by immunoabsorption.—

—61. The method of Claim 17, wherein concentration is effected by immunoabsorption.—

—62. The method of Claim 20, wherein the cell separation medium has a density in the range of from 1.055 to < 1.070 g/ml.—

—63. The method of Claim 62, wherein the density is about 1.065 g/ml.—

—64. The method of Claim 25, wherein the peripheral blood is drawn in an anticoagulant substance and, prior to covering the cell separation medium, diluted with a diluent at a ratio of about 1:1.—

—65. The method of Claim 31, wherein at least one of the porous barrier, the filter or the sieve has a thickness of about 5 mm.—

—66. The method of Claim 30, wherein at least one of the porous barrier, the filter or the sieve has a pore size of 20-30 μm .—

PRELIMINARY AMENDMENT

—67. The method of Claim 1, wherein the tumor cells are derived from micrometastases of malignant tumors.—

—68. The kit of Claim 44, wherein the labeled oligonucleotide comprises the sequence 5' CGTTCTGGCT CCCACGACGT AGTC 3' SEQ ID No. 9, designated hTRTo or the corresponding reverse complementary sequence thereof.—

Please amend claims 1-51 as follows:

1. (Amended) [Method] A method for the quantification of tumor cells in a body fluid, [characterized in that] comprising:

(a) concentrating [the sample to be investigated is subjected to a method for concentrating] or depleting tumor cells in a sample of a body fluid; and

(b) specifically amplifying] a reaction is carried out, on the concentrated or depleted tumor cells, in which the] mRNA coding for the catalytic subunit of telomerase;[is specifically amplified,] and

(c) quantitatively determining the amount of amplified nucleic acid[is determined quantitatively], thereby quantifying tumor cells in a body fluid.

2. (Amended) The method of [Method according to] Claim 1, further comprising[characterized in that] prior to amplification, preparing cDNA from [reverse transcription reaction in which] the mRNA contained in the sample [is transcribed into cDNA is carried out before the amplification reaction with the sample to be investigated].

3. (Amended) [Method according to Claims 1 or 2, characterized in that] The method of Claim 2, wherein, prior to preparing cDNA, the [a DNase reaction is carried out with] the sample is treated with a DNAase[to be investigated before the transcription of the mRNA into cDNA].

4. (Amended) [Method according to any of Claims 1 - 3, characterized in that] The method of Claim 1, wherein the sample [to be investigated] is purified[, preferably by an ion exchange chromatography, in particular on silica gel].

PRELIMINARY AMENDMENT

5. (Amended) [Method according to any of Claims 1 - 4, characterized in that] The method of Claim 1, wherein[,] for quantitative determination of the telomerase-coding nucleic acid, the amplification products are labeled [even] during amplification and the amplification kinetics are measured continuously, including [even] during the amplification process.

6. (Amended) [Method according to] The method of Claim 5, [characterized in that] wherein a probe [which] that is specific for the amplification products, and [which] that emits a characteristic signal proportional to the products amplified per synthesis cycle, is present during amplification.

7. (Amended) [Method according to any of Claims 1 - 4, characterized in that] The method of Claim 1, wherein for quantitative determination of the telomerase-encoding nucleic acid, at least one[, preferably three,] standard nucleic [acids are] acid molecule is coamplified and [are] added in different concentrations to the sample[to be investigated].

8. (Amended) [Method according to any of Claims 1 - 7, characterized in] The method of Claim 1, wherein [that] the amplification product is quantified either directly or via a label[, preferably via a radioactive label, a biotin label, a fluorescent label or an electrochemoluminescent label].

9. (Amended) [Method according to any of Claims 1 - 7, characterized in that] The method of claim 1, wherein the amplification product is detected via [a] hybridization with a labeled oligonucleotide[, where the label is preferably a radioactive label, a biotin label, a fluorescent label or an electrochemoluminescent label].

10. (Amended) [Method according to any of Claims 7 - 9, characterized in that] The method of Claim 7, wherein quantification of[, to quantify] the telomerase-encoding nucleic acid is effected by comparing [to be determined,] the amount of coamplified nucleic acid or nucleic acids [is compared] with the amount of telomerase-encoding nucleic acid.

PRELIMINARY AMENDMENT

11. (Amended) [Method according to any of Claims 1 - 10, characterized in that] The method of claim 1, wherein the sample [to be investigated] is peripheral blood[, and in that a reaction is carried out with the sample to be investigated as positive control, in which a nucleic acid which occurs in peripheral blood, preferably the mRNA coding for β -globin, glyceraldehyde-phosphate dehydrogenase, β -actin or the T-cell receptor, is specifically amplified and detected].

12. (Amended) [Method according to Claim 1 or any of Claims 3 - 11, characterized in that] The method of Claim 1, wherein as a negative [controls] control, no reverse transcription reaction is carried out before the amplification reaction with the sample to be investigated and/or water is employed in place of the body fluid.

13. (Amended) [Method according to any of Claims 1 - 12, characterized in that] The method of Claim 1, wherein one or both of the following oligonucleotide primers are used for the amplification:

5' CTACCGGAAG AGTGTCTGGA GCAAGTTGGA AAGC 3' SEQ ID No. 1, designated [(]hTRT1[)];

[and/or] and

5' GGCATACCGA CGCACGCAGT ACGTGTTCTG 3' SEQ ID No.2, designated [(]hTRT2[)],

wherein each of [where] hTRT1 [and/or] and hTRT2 optionally further comprises [where appropriate] a promoter sequence for an RNA polymerase.

14. (Amended) [Method according to any of Claims 1 - 13, characterized in that] The method of Claim 1, wherein amplification is effected with a DNA polymerase or an RNA polymerase[is used for the amplification].

15. (Amended) [Method according to any of Claims 1 - 14, characterized in that] The method of claim 14, wherein[, in the case of] if amplification is effected with a DNA polymerase, the amplification reaction is a [the] polymerase chain reaction (PCR)[is carried out] and, [in the case of] if

PRELIMINARY AMENDMENT

amplification is effected with an RNA polymerase, the reaction is an isothermal nucleic acid sequence-based amplification (NASBA) reaction[is carried out].

16. (Amended) [Method according to any of Claims 1 - 15, characterized in that] The method of claim 1, wherein the sample [to be investigated] is blood that is[, and in that the blood sample to be investigated is] depleted in stem cells and/or activated immune cells[, preferably by immunoabsorption].

17. (Amended) [Method according to any of Claims 1 - 16, characterized in that] The method of Claim 1, wherein the sample [to be investigated] is blood, and the tumor cells from the blood sample[to be investigated] are concentrated[, preferably by immunoabsorption].

18. (Amended) [Method according to any of Claims 1 - 17, characterized in that] The method of Claim 1, wherein the cells contained in the sample are cultivated under conditions [which] that are unfavorable for telomerase-positive nontumor cells but favorable for the tumor cells present.

19. (Amended) [Method according to Claim 18, characterized in that] The method of Claim 18, wherein the duration of the cultivation is such that nontumor cells die and tumor cells survive.

20. (Amended) [Method according to any of Claims 1 - 19, where,] The method of Claim 1, wherein for concentrating the tumor cells, a cell separation medium is covered with a layer of the body fluid and centrifuged[, characterized in that the cell separation medium has a density in the range from 1.055 to < 1.070 g/ml].

21. (Amended) [Method according to Claim 20, characterized in that] The method of Claim 20, wherein the cell separation medium has a density in the range of from 1.060-1.067 g/ml[and preferably of about 1.065 g/ml].

22. (Amended) [Method according to Claim 20 or 21, characterized in that] The method of Claim 20, wherein the centrifugation is carried out at about 1000 x g for about 30 minutes.

PRELIMINARY AMENDMENT

23. (Amended) [Method according to any of Claims 20 - 22, characterized in that] The method of Claim 20, wherein the cell separation medium used is Percoll or Ficoll.

24. (Amended) [Method according to any of Claims 20 - 23, characterized in that the body fluid is,] The method of Claim 20, wherein prior to applying the body fluid sample to the cell separation medium, it is mixed [being applied as a covering layer, admixed] with one or more substances [which] that prevent aggregation of platelets to tumor cells, and/or [the body fluid is,] prior to [being applied as a covering layer,] applying the body fluid sample to the cell separation medium, it is freed of substances [which] that promote aggregation of platelets to tumor cells.

25. (Amended) [Method according to any of Claims 20 - 24, characterized in that] The method of Claim 20, wherein the body fluid is peripheral blood.

26. (Amended) [Method according to Claim 25, characterized in that] The method of Claim 25, wherein the peripheral blood is drawn in an anticoagulant substance and, prior to covering the cell separation medium, diluted with a diluent[, preferably in a ratio of about 1:1].

27. (Amended) [Method according to Claim 25 or 26, characterized in that] The method of Claim 25, wherein the peripheral blood is venous or arterial blood.

28. (Amended) [Method according to any of Claims 20 - 24, characterized in that] The method of Claim 20, wherein the body fluid is selected from the group consisting of lymph, urine, exudates, transudates, spinal fluid, seminal fluid, saliva, fluids from natural or unnatural body cavities, bone marrow and dispersed body tissue.

29. (Amended) [Method according to any of Claims 20 - 28, characterized in that] The method of Claim 20, wherein [the centrifugation vessel is,] after centrifugation and before the tumor-cell-enriched interphase,

PRELIMINARY AMENDMENT

the centrifugation vessel is removed[,] and cooled intensively to prevent mixing of the cells in the different layers.

30. (Amended) [Method according to any of Claims 20 - 29, characterized in that] The method of Claim 20, wherein the centrifugation is carried out in a vessel [which] that is divided by a porous barrier, a filter or a sieve into an upper and a lower compartment and the body fluid is introduced into the upper compartment.

31. (Amended) [Method according to] The method of Claim 30, wherein [characterized in that] at least one of the porous barrier, the filter or the sieve [have] has a thickness of 1-10 mm[, preferably about 5 mm].

32. (Amended) [Method according to Claim 30 or 31, characterized in that] The method of Claim 30, wherein at least one of the porous barrier, the filter or the sieve [have] has a pore size of 20-100 μm [, preferably 20-30 μm].

33. (Amended) [Method according to any of Claims 30 - 32, characterized in that] The method of Claim 30, wherein at least one of the porous barrier, the filter or the sieve [are] is fabricated from [made of] a hydrophobic material or coated with a hydrophobic material.

34. (Amended) [Method according to any of Claims 20 - 33, characterized in that] The method of Claim 20, wherein the cell separation medium contains a dye, [which makes the] whereby the color of the cell separation medium is distinguishable from that of the supernatant body fluid[, thus simplifying the localization of the interphase].

35. (Amended) [Method according to any of Claims 1 - 34, characterized in that] The method of Claim 1, wherein: the sample [to be investigated] is blood;

the method is performed[and in that there is an investigation in said method of], on [the one hand,] a venous blood sample and on [the other hand,] an arterial blood sample[,] and the results from each are compared with one another.

PRELIMINARY AMENDMENT

36. (Amended) [Method according to any of Claims 1 - 35, characterized in that] The method of Claim 1, wherein: the sample [to be investigated] is blood;

the method is performed[, and in that there is an investigation in said method of,] on [the one hand,] a blood sample from the finger pad and, on [the other hand,] a venous or arterial blood sample;[,] and

the results from each are compared with one another.

37. (Amended) [Method according to any of claims 1 - 36, characterized in that] The method of Claim 1, wherein the tumor cells are derived from metastases[, preferably micrometastases,] of malignant tumors.^C

38. (Amended) [Method according to any of Claims 1 - 37, characterized in that] The method of Claim 1, wherein the tumor cells are selected from [a group of] cells of metastasizing tumors and/or neoplasms, wherein the cells [which] are derived from tumors and cells selected from the group consisting of a T-cell lymphoblastoma, T-cell leukemia cells, chronic myeloid leukemia cells, acute lymphatic leukemia cells, chronic lymphatic leukemia cells, teratocarcinoma, melanoma, carcinoma of the lung, large intestine cancer, breast cancer, hepatocellular carcinoma, kidney tumor, adrenal tumor, prostate carcinoma, neuroblastoma, brain tumor, rhabdomyosarcoma, leiomyosarcoma [and/or] and lymphoma cells.

39. (Amended) An oligonucleotide [Oligonucleotide] primer, [with] comprising the sequence

5' CTACCGGAAG AGTGTCTGGA GCAAGTTGCA AAGC 3' SEQ ID No. 1, designated [(]hTRT1[)] and/or] or

5' GGCATACCGA CGCACCGCAGT ACGTGTTCTG 3' SEQ ID No. 2, designated [(]hTRT2[)],
[where] wherein hTRT1 [and/or] and hTRT2 [may, if appropriate, additionally] optionally comprise a promoter sequence for an RNA polymerase.

PRELIMINARY AMENDMENT

40. (Amended) An oligonucleotide [Oligonucleotide] probe[with], comprising the sequence
5' CGTTCTGGCT CCCACGACGT AGTC 3'SEQ ID No. 9, designated [(]hTRT o[)]
[and/or] or the corresponding reverse complementary sequence thereof.

41. (Amended) A kit [Kit] for the quantification of tumor cells in a body fluid, comprising[: (a)] an oligonucleotide primer pair for specific amplification of mRNA encoding the catalytic subunit of telomerase [telomerase-encoding mRNA].

42. (Amended) The kit of [Kit according to] Claim 41, [characterized in that] wherein the oligonucleotide primer pair specified [in (a) has the following sequences] comprises one or both of :

5' CTACCGGAAG AGTGTCTGGA GCAAGTTGCA AAGC 3' SEQ ID No. 1, designated [(]hTRT1[)]
[and/or] and

5' GGCATACCGA CGCACGCAGT ACGTGTTCTG 3' SEQ ID No. 2, designated [(]hTRT2[)],
[where] wherein hTRT1 [and/or] and hTRT2 [comprises where appropriate] optionally further comprise a promoter sequence for an RNA polymerase.

43. (Amended) The kit of [Kit according to either of Claims 41 or 42, characterized in that it additionally comprises (b)] Claim 41, further comprising a standard nucleic acid or standard nucleic acids for coamplification.

44. (Amended) The kit of Claim 4, [Kit according to any of Claims 41 - 43, characterized in that it additionally comprises] further comprising a labeled oligonucleotide for detecting the amplified nucleic acid of the sample to be determined and/or one or more labeled oligonucleotides for detecting the coamplified standard nucleic acid or standard nucleic acids[, in particular an oligonucleotide with the sequence:

5' CGTTCTGGCT CCCACGACGT AGTC 3'(hTRT₀)
and/or the corresponding reverse complementary sequence thereof].

PRELIMINARY AMENDMENT

45. (Amended) [Kit according to any of Claims 41- 44, characterized in that it additionally comprises] A kit of Claim 41, further comprising one or more of a reverse transcriptase, a DNA polymerase[, preferably a Taq polymerase,] a DNase[, and/or suitable] buffers[and, where appropriate], labeled nucleotides[and, where appropriate], means [suitable] for the depletion of stem cells and/or activated immune cells [and/or] and means for the concentration of tumor cells.

46. (Amended) [Kit according to any of Claims 41 - 45, characterized in that it additionally comprises] A kit of Claim 41, further comprising one or more of a reverse transcriptase, an RNA polymerase[, preferably a T7 RNA polymerase,] an RNase H, a DNase[and/or suitable] buffers[and, where appropriate], labeled nucleotides and[, where appropriate], means [suitable] for the depletion of stem cells and/or activated immune cells and/or for the concentration of tumor cells.

47. (Amended) [Kit according to any of Claims 41 - 46, characterized in that it additionally comprises] The kit of Claim 41, further comprising a cell separation medium having a density in the range of from 1.055 to < 1.070 g/ml and[, if appropriate,] optionally a centrifugation vessel.

48. (Amended) [Kit according to] The kit of Claim 47, [characterized in that] wherein the cell separation medium has a density in the range of from 1.060 to 1.067 g/ml[and preferably of about 1.065 g/ml].

49. (Amended) [Kit according to either of Claims 47 or 48, characterized in that] The kit of Claim 47, wherein the centrifugation vessel has a porous barrier, a filter or a sieve of a thickness of 1-10 mm[, preferably of about 5 mm], which [divide] divides the centrifugation vessel into an upper and a lower compartment.

50. (Amended) [Kit according to] The kit of Claim 49[, characterized in that] wherein the porous barrier, the filter or the sieve [have] has a pore size of 20-100 μm [, preferable 20-30 μm].

National Stage of International Appln. No.: PCT/EP99/00716

DAHM *et al.*

PRELIMINARY AMENDMENT

51. (Amended) [Kit according to Claim 49 or 50, characterized in that]

The kit of Claim 49, wherein the cell separation medium is in the lower compartment of the centrifugation vessel.

REMARKS

Claims 1-68 are presently pending. The claims are amended and new claims added herein to delete multiple dependencies and to put the claims into a form that better comports with U.S. practice. Therefore, no new matter has been added.


It is respectfully requested that any references of record in the International stage of prosecution of this application be made of record in this application.

* * *

In view of the above amendments and remarks, reconsideration and allowance of the application are respectfully requested.

Respectfully submitted,
HELLER EHRLMAN WHITE & McAULIFFE LLP

By:


Stephanie Seidman
Registration No. 33, 779

Attorney Docket No. 24741-1509US

Address all correspondence to:

Stephanie Seidman
HELLER EHRLMAN WHITE & McAULIFFE LLP
4250 Executive Square, 7th Floor
La Jolla, California 92037
Telephone: 858 450-8400
Facsimile: 858 587-5360
email:sseidman@HEWM.com

1201 PCT/4

09/601645
526 Rec'd PCT/PTC 04 AUG 2000

February 3, 1999
K/T/sm

Method for the quantitative determination of tumor cells in a body fluid and test kits suitable therefor

5 The invention relates to a method for the quantification of tumor cells in a body fluid, in which firstly the sample to be examined is subjected to a process for the enrichment or depletion of tumor cells and a reaction is carried out on the enriched or
10 depleted tumor cells in which the mRNA encoding the catalytic subunit of the telomerase is specifically amplified, and subsequently the amount of amplified nucleic acid is determined quantitatively, and to test kits suitable therefor.

15 Virtually all solid malignant tumors have the potential to form metastases. The metastasis process comprises the spread of malignant cells as micro-metastases, usually via the blood or lymph to remote organs and the development of autonomous secondary
20 tumors. The extent of metastasis determines the prognosis of an oncosis.

25 The requirements of tumor prevention or after-care programs are to diagnose primary tumors or a recurrence or a metastasis early, even before metastases become clinically manifest. This aim cannot yet be satisfactorily met with the available instrumental techniques; in particular, there is still a diagnostic gray zone between the detection of circulating tumor cells and incipient formation of metastases in organs.
30 Early diagnosis of circulating malignant cells, for example in peripheral blood of a patient undergoing tumor aftercare, would make it possible to introduce immunomodulating therapy or polychemotherapy, which is possibly curative, at an early date, that is to say even before organ metastasis becomes manifest.
35 Quantification of the tumor cells in peripheral blood before and after the therapy represents an important control in such cases.

The life span of eukaryotic cells is, according to the telomer hypothesis, determined by the length of the termini of the chromosomal DNA, the telomeres. Thus, according to this theory, telomeres have the function of 5 a mitotic clock. Because of the replication mechanism of the DNA polymerases, the telomeres are shortened after each cell division by the length of the replication primer. As a consequence, after each cell division, the chromosomes are shorter, reaching a 10 critical length after a certain number of cell divisions. The cells then proceed into a senescent phase where they no longer divide and finally die. However, in some cases this regulation mechanism can be bypassed by a ribonuclearprotein, the telomerase, and 15 the cells become immortal. The telomerase synthesizes, at the 5'-end of the chromosomes, the telomer sequences lost during replication, where the RNA component of the protein (human Telomerase RNA component, hTR) serves as matrix and part of the protein component forms the 20 catalytic subunit (human Telomerase Reverse Transcriptase, hTRT).

In humans, the cells with active telomerase and unlimited life expectancy are, in particular, the germ cells and the hemopoietic stem cells, which are capable 25 of dividing during the entire life span of a person. In addition, increased telomerase activities are also found on activated human B and T lymphocytes. Besides this normal physiological role of telomerase, an increased telomerase activity is found in about 90-95% 30 of all human tumor tissues. The telomerase activity of tumor cells can therefore form the basis for a detection system for disseminated circulating tumor cells in body fluids, which may potentially give rise to metastases.

35 Telomerase is a ribonucleoprotein with reverse transcriptase activity [Shippen-Lentz et al. (1990), Science 247: 546] which uses an integral RNA sequence as template for independent DNA synthesis [Greider et al. (1989). Nature 337: 331] by which new telomeric DNA

are synthesized at the ends of the chromosomes. Telomeres consist of highly conserved (TTAGGG)_n in tandem sequences with a length of about 5-15 kilobases (kb)/cell genome and have the task of stabilizing the 5 chromosomes on the nuclear membrane and protect the coding genomic DNA from uncontrolled recombination and degradation [Mehle et al. (1994). *Cancer Res* 54: 236]. Whereas a dynamic equilibrium between shortening of the chromosome ends and de novo synthesis of telomeric 10 sequences by telomerase is postulated in lower eukaryotes, normal human somatic cells show low or undetectable telomerase activity. In addition, telomerase is not growth-regulated, in contrast to other DNA enzymes, since none of the actively proliferating 15 cell cultures showed detectable telomerase activity. Only germ cells and almost all tumor cell lines [Ohyashiki et al. (1994). *Cancer Genet Cytogenet* 78:64; Rogalla et al. (1994). *Cancer Genet Cytogenet* 77: 19; Schwartz et al. (1995). *Cancer* 75: 1094] and tumor 20 tissues (Lunge, [Hiyama et al. (1995). *Oncogene* 10: 937; Shirotani et al. (1994). *Lung Cancer* 11: 29], kidneys [Mehle et al. (1994). *Cancer Res* 54: 236], ovaries [Chadeneau et al. (1995). *Cancer Res* 55: 2533] and blood [Counter et al. (1995). *Blood* 85: 2315]) show 25 measurable telomerase activity and a constant telomere length which is retained throughout an infinite number of cell divisions. Activation of telomerase with the stabilization, associated therewith, of the telomere length can therefore be regarded as a critical step in 30 the direction of immortalization of somatic cells.

Feng et al. were able to clone the integral RNA sequence of human telomerase (hTR), which is encoded on the distal segment (q) of chromosome 3. The authors were able to demonstrate, by competitive polymerase 35 chain reaction (PCR), a significant increase in telomerase expression in tumor tissues and in germinal tissues by comparison with normal somatic cells [Feng et al. (1995), *Science* 269: 1236]. An antisense construct of the hTR sequence caused cell death

(apoptosis) in transfected HeLa cells. These data demonstrate stringent repression of telomerase in somatic tissues, as well as the fact that malignant growth depends on the presence of immortal cells and on 5 the activation of telomerase.

In 1997, Nakamura et al. characterized a protein component of the catalytic subunit of human telomerase. In comparison with the RNA component of human telomerase (hTR), the mRNA encoding the catalytic 10 subunit of human telomerase (hTRT) correlates considerably better with the telomerase activity (Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J, Harley CB, Cech TR (1997): Telomerase catalytic subunit homologs from fission 15 yeast and human. *Science* 277: 955-9) and is therefore more suitable for cancer diagnosis. Meyerson et al. localized hTRT on the human chromosome 5p and confirmed the strong correlation of the hTRT mRNA detection with the enzymatic activity of human telomerase (Meyerson M, 20 Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddle SD, Ziaugra L, Beijersbergen RL, Davidoff MJ, Liu Q, Bacchetti S, Haber DA, Weinberg RA (1997): hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. 25 *Cell* 90: 785-95).

Currently, the standard method for determining the catalytic activity of telomerase is the TRAP assay (Telomeric Repeat Amplification Protocol) [Kim et al. *Science* (1994) 266: 2011]. Here, the telomerase present 30 in cell extract synthesizes extension products which are subsequently amplified in a polymerase chain reaction (PCR). A densitometric evaluation of the amplification products then permits quantification of the telomerase activity. Depending on the sample 35 material, the test laboratory and the protocol used, the sensitivity of the TRAP assay was stated as being 4-100 cells/batch. Since the crude extract of lysed cells or tissues is used in the TRAP assay, this method

is highly susceptible to interference by inhibitors of the DNA polymerase used in PCR (Taq polymerase).

The TRAP assay is used, for example in WO 98/02581, for the diagnosis of precancerous or 5 cancerous damage to the cervix, endocervix, the vagina or vulva.

WO 97/18322 discloses a method for the quantification of tumor cells in which initially a reaction is carried out with the sample to be tested 10 where the RNA component of the telomerase is specifically amplified, and the amount of amplified nucleic acid is subsequently determined quantitatively.

WO 96/01835 likewise discloses a method for the detection of the RNA component of telomerase in cells 15 or cell samples.

In spite of the known methods for detecting tumor cells, there is still a need for reliable and simple methods for quantifying tumor cells in body fluids.

20 The object of the present invention was therefore to develop a method with which it is possible to determine tumor cells quantitatively in a body fluid.

The invention therefore relates to a method for 25 the quantification of tumor cells in a body fluid, in which firstly the sample to be examined is subjected to a process for the enrichment or depletion of tumor cells and a reaction is carried out on the enriched or 30 depleted tumor cells in which the mRNA encoding the catalytic subunit of the telomerase is specifically amplified, and subsequently the amount of amplified nucleic acid is determined quantitatively, and to test kits suitable therefor.

The body fluid in which the tumor cells are to 35 be quantified can be any human or animal body fluid or a dispersion of cell tissue. It is, for example, blood, in particular peripheral blood, such as venous or arterial blood, lymph, urine, stool, exsudates, transudates, spinal fluid, seminal fluid, saliva,

liquids from natural or unnatural body cavities, bone marrow and disperse body tissue. The fluids from natural body cavities can, for example, be serous fluids such as peritoneal and pleura fluids, the fluids from unnatural body cavities can, for example, be fluids from cysts.

Preferred body fluids are blood, bone marrow, lymph, serous fluids from body cavities and urine, and particular preference is given to blood and urine. 10 Urine is particularly suitable for enriching cells from bladder tumors.

Peripheral blood is, for example, taken from the subject by puncturing an artery, vein or finger pad and, after an enrichment or depletion process, the tumor cells contained in the sample are transferred into an RNA lysis buffer which comprises, for example, urea or, preferably, guanidinium isothiocyanate, in order to denature any RNases present and to release the nucleic acids from the cells [see, for example, Chomczynski et al. (1987) *Anal. Biochem.* 162, 156]. The nucleic acids can be isolated from the strongly saline medium of the RNA lysis buffer, for example, by means of silica particles to which all nucleic acids are able to bind [Boom et al. (1990) *J. Clin. Microbiol.*, 29, 495]. The particles are then washed several times with suitable buffer and the bound nucleic acids are eluted. It is subsequently advantageous to hydrolyze any genomic DNA present in the sample using RNase-free DNase in a suitable buffer, so that no false-positive results or excessive background noise result due to false amplification signals, because DNA is possibly still present, in the later amplification of the mRNA which codes for the catalytic subunit of telomerase. This is generally followed by inactivation of the DNase, for example by phenol extraction and/or heat denaturation. It is possible and advantageous, before or, preferably, after treatment of the sample with DNase, also to purify the RNA present in the sample

further, for example by chromatographic methods such as ion exchange chromatography, preferably on silica gel.

To check whether possibly interfering genomic DNA is still present in the sample, it is subsequently 5 possible to carry out an amplification reaction with the telomerase-specific oligonucleotide primers which are described hereinafter, in which case the RNA present in the sample is not transcribed to cDNA by a reverse transcription reaction beforehand. Only in the 10 case where the sample is free of telomerase-specific DNA does no amplification take place, with the result that no amplified DNA can be measured.

This is followed by transcription of the RNA present in the sample into cDNA, generally by means of 15 the reverse transcription reaction, for example with AMV reverse transcriptase. The method is generally known and is described, for example, in Sambrook et al., Molecular Cloning: A Laboratory Manual, New York Cold Spring Harbor Laboratory, 1989. In a preferred 20 embodiment of the reverse transcription, it is also possible to use a thermostable RNA-dependent DNA polymerase as described in WO 90/07641. Suitable oligonucleotide primers for the reverse transcriptase are, for example and advantageously, the oligonucleotide 25 primers described below or random primers with a particular length.

The subsequent amplification can be carried out, for example, with a DNA polymerase, for example by the polymerase chain reaction (PCR) (see, for example, 30 U.S. Patent Nos. 4,683,195; 4,683,202; 4,965,188) or, preferably, with an RNA polymerase by, for example, isothermal nucleic acid sequence-based amplification (NASBA). Specific oligonucleotide primers derived from 35 the nucleic acid to be amplified are required for the amplification in each case. It is possible in the present invention to use any sequence section of the cDNA coding for the catalytic subunit of telomerase for synthesizing the oligonucleotide primers. The oligonucleotide primers are preferably about 20 to

about 40, preferably about 25 to 35, nucleotides long. The amplification product is generally about 100 to about 2000 bases, preferably about 200 to about 1500 bases, in particular about 450 to about 550 bases, 5 long. The following oligonucleotide primers, which have been derived from the sequence shown in Fig. 1, are particularly preferred for the novel method:

10 5' CTACCGGAAG AGTGTCTGGA GCAAGTTGCA AAGC 3' (hRT1),
and/or
5' GGCATACCGA CGCACGCAGT ACGTGTTCTG 3' (hRT2),

15 where hRT1 and/or hRT2 may, where appropriate, additionally comprise a promoter sequence for an RNA polymerase. The oligonucleotide primer hRT1 corresponds to the 5' primer and hRT2 corresponds to the 3' primer. The amplification product is 513 bp long. The primers may, for example, be prepared synthetically using the triester methods [Matteucci et 20 al., (1981), J. Am. Chem. Soc., 103, 3185-3191]. The DNA polymerase which can be used is, for example, a non-thermostable DNA polymerase such as T4 DNA polymerase, T7 DNA polymerase, E. coli polymerase I or the Klenow fragment of E. coli or, preferably, a 25 thermostable DNA polymerase such as Taq polymerase (see, for example, U.S. Patent No. 4,889,818).

30 The general principle of the PCR reaction [sic] consists of heat-denaturation of the DNA and restoration of the double strand in the presence of suitable oligonucleotide primers with opposite orientation of the single strand using DNA polymerase in several repeated reaction cycles. The cycle is then repeated until sufficient DNA has been formed for quantification by one of the methods described below. 35 In general, about 20 to about 40 cycles, preferably about 30 to about 35 cycles, suffice.

In the NASBA method (also called 3SR system) there is use of at least one oligonucleotide primer, preferably hRT2, which comprises a promoter for the

RNA polymerase, preferably for T7 RNA polymerase [see, for example, Guatelli et al. (1990) Proc. Natl. Acad. Sci. USA, 87, 1874-1878 or Kievits et al. (1991), J. Virol. Methods, 35, 273-286]. Firstly, as already 5 described in detail above, the RNA is transcribed with the aid of one of the oligonucleotide primers described above and of a reverse transcriptase, preferably AMV reverse transcriptase, into cDNA. The reaction product is an RNA:DNA double strand whose RNA component is then 10 degraded by an RNase, preferably RNase H, to give a DNA single strand. Using one of the oligonucleotide primers described above, the DNA single strand is made up to the DNA double strand using a DNA polymerase. AMV reverse transcriptase is once again a suitable and 15 preferred DNA polymerase because this transcriptase has not only an RNA-dependent DNA polymerase activity but also a DNA-dependent DNA polymerase activity. The reaction product is a DNA double strand which comprises the promoter for, for example, T7 RNA polymerase. The 20 RNA polymerase then synthesizes an "antisense" RNA strand again, and the cycle can begin again. In general, about 20 to about 40 cycles, preferably about 30 to about 35 cycles, suffice to provide sufficient 25 amplification product, preferably "antisense" RNA, for the subsequent quantification.

The amplification products can be quantified by, for example, staining with intercalating fluorescent dyes such as, for example, ethidium bromide and direct visualization and quantification, for example in an agarose or polyacrylamide gel under ultraviolet light.

However, since the amplification products to be quantified are in direct correlation with the amount of RNA employed only when the amplification reaction is in a linear phase, it is necessary for quantification to measure the course of the reaction of the amplification. To this end, the reaction products have to be measured after each amplification cycle, and the linear range in which quantification can be carried out

with sufficient certainty is determined using the course of the reaction. Thus, it is advantageous if the amplification products are labeled even during amplification and the kinetic of the amplification is measured continuously even during the amplification process. In the case of the TaqMan™-PCR (Hoffmann-La Roche), for example, this is carried out with the aid of a probe which is specific for the amplification product. At its 3' and 5' ends, the probe is labeled with different fluorescent dyes ("Reporter" and "Quencher"), and the probe is present in the reaction vessel during the entire PCR. Owing to the 5'-3'-exonuclease activity of the DNA polymerase used for amplification (AmpiTaq™, Hoffmann-La Roche), the probe is hydrolyzed during prolongation of the DNA daughter strand, and in the process, the quencher is separated from the reporter. As a consequence, the quench effect is terminated and the characteristic fluorescence emitted by the "reporter" can be measured. The intensity of this fluorescence is directly proportional to the PCR products which were amplified per synthesis cycle.

Other examples of suitable labels are radioactive labels, biotin labels, fluorescent or electrochemoluminscent (ECL) labels. In general, the labels are attached to the nucleotides as starting materials for amplification by DNA or RNA polymerase. The radiolabeled amplification products (for example PCR or NASBA products) can be detected by measuring the radioactivity, the biotin-labeled amplification products can be detected via a dye which carries avidin or streptavidin, the fluorescent-labeled amplification products can be detected with a fluorometer and the electrochemoluminscent-labeled amplification products can be detected with an ECL detector. However, the most preferred detection method is automatic *in vitro* hybridization, such as, for example, in the case of TaqMan™-PCR, even during the amplification process.

In contrast to "real time" quantification of PCR products as in the case of TaqManTM-PCR, it is also possible to quantify PCR products using dilution series. To this end, the RNA or the corresponding cDNA 5 is employed in various dilutions. This gives, similar to the "real time" quantification, a sigmoidal reaction kinetic where once more in the linear range the amplification products are proportional to the starting material. The PCR products are detected with the aid of 10 fluorescent-dye-labeled or radiolabeled deoxy-nucleotides which are incorporated directly into the PCR products by DNA polymerase during amplification. Furthermore, oligonucleotides (so-called primers which 15 are required in the PCR for initializing the synthesis of the daughter strand and which are present in all amplification products incorporated at the 5' and 3' end of the DNA after PCR) are labeled with certain molecules (for example biotin) to immobilize the amplification products after PCR with the aid of 20 specific antibodies or streptavidin. This immobilization can be carried out, for example, in a microtiter plate, in which, subsequently, a color reaction can take place with the aid of a molecular-labeled specific probe which hybridizes with the 25 amplification products and with the aid of an enzyme-coupled (for example peroxidase-coupled) antibody against the marker molecule of the probe. This color reaction can subsequently be evaluated photometrically.

The oligonucleotide for detection by in vitro 30 hybridization generally carries the labels described above, and in connection with the NASBA amplification method the hybridization probe carries an electrochemoluminsecent label, preferably a tris[2,2-bipyridine]ruthenium[II] complex label [see, 35 for example, van Gemen et al. (1994), J. Virol. Methods, 49, 157-168].

Accurate and sensitive quantification of the amplification products can also advantageously be achieved by coamplification of a defined amount of one

or more known nucleic acids (standard nucleic acids) [see, for example, van Gemen et al. (1993), J. Virol. Methods, 43, 177-188]. In this case, a different but exactly known amount of the coamplifying standard 5 nucleic acid or nucleic acids is added, for example in the form of a dilution series, to the unknown amounts of the sample to be investigated, and the amplification products of the sample and one or more coamplifying standard nucleic acids are determined quantitatively in 10 independent mixtures. Comparison of the measured results reveals the amount of the mRNA coding for the catalytic subunit of telomerase to be determined in the sample.

It is advantageous to amplify the coamplifying 15 standard nucleic acid or nucleic acids with the same oligonucleotide primer as the sample to be investigated and the amplification products also have essentially the same length. It is particularly preferred for the coamplifying nucleic acids to have the same sequence as 20 the amplification product of the sample to be determined, with the exception of about 20 nucleic acids between the oligonucleotide primer binding sites, which have an arbitrary but known sequence. It is possible thereby to quantify, independently of one another, the 25 amplification product to be determined in the sample from the coamplifying amplification product, for example by a hybridization as described in detail, for example, in Sambrook et al. (supra), using appropriately complementary labeled oligonucleotides. It is 30 particularly advantageous if several, preferably three, different coamplifying nucleic acids are added in different concentrations to the sample, because this makes it possible to reduce the number of individual amplification reactions which would otherwise have to 35 be carried out [see van Gemen et al. (1994) J. Virol. Methods 49, 157-168]. It is also particularly preferred to add the coamplifying nucleic acids to the RNA lysis buffer described above because it is possible thereby

to exclude the effect of possible nucleic acid losses in the subsequent workup of the sample.

Suitable and advantageous coamplifying standard nucleic acids in the present invention are RNA single stranded sequences which are prepared by in vitro transcription, for example with Sp6 or T7 RNA polymerase, from constructs which comprise the DNA or cDNA of the sample to be amplified and which are in each case provided with a randomized exchange of a sequence of, for example, about 10 to about 30, preferably about 20, nucleotides.

The constructs preferably consist of a transcription vector having a binding site for Sp6 or T7 RNA polymerase between a "multiple cloning site" in which the DNA or cDNA of the sample to be amplified has been cloned. The cloned sequence can be opened by selective hydrolysis with restriction endonucleases, preferably with two different restriction endonucleases, and a fragment of a defined length can be cut out and replaced by a fragment of equal length, for example using T4 ligase. The cloned fragment may comprise replacement of a sequence of any length, for example about 10 to about 30, preferably about 20, nucleic acids and is preferably located between the oligonucleotide primer binding sites. This procedure can be repeated in order to insert other nucleic acid sequences at the same site. If no suitable cleavage sites can be found, for example because the vector is also cut, it is necessary to create artificial cleavage sites. This can take place, for example, by recombinant PCR which is described in essence by Higuchi et al. [Higuchi, R. (1988). Nucleic Acid Res 16: 7351-7367; Higuchi, R. (1990). M. Innis A. et al. eds. San Diego, New York, Berkley, Boston, London, Sydney, Tokyo, Toronto, Academic Press, Inc. 177-183] and in the experimental part of the present invention.

Preferably used for the purpose of the invention are in vitro transcribed RNA single stranded sequences of constructs which

a) comprise the entire cDNA corresponding to the mRNA which codes for the catalytic subunit of human telomerase and

5 b) in which a randomized exchange of a sequence of about 20 nucleotides has been introduced.

Since the standard nucleic acids (for example, hTRTKa, hTRTKb and hTRTKc) differ from one another and from the wild-type sequence for example only by a 10 randomized and known sequence which is 20 base pairs long, the amplification products of the standard nucleic acids and of the wild-type sequence can be detected by complementary binding of labeled oligonucleotides in four separate mixtures.

15 The corresponding reverse complementary sequences are used to detect the amplified "antisense" RNA.

After this, the individual amplified amounts of the wild-type and standard nucleic acids are 20 determined. The unknown initial amount of the wild-type sequence can be calculated by comparing with the different amplified amounts of the standard nucleic acids when the initial amount is known (for example hTRKa: 10^2 , hTRKb: 10^4 and hTRKc: 10^6 molecules). It is 25 then possible to conclude from this the number of metastases for the removed body fluid.

As internal positive control of the method and of the sample to be investigated it is possible additionally to amplify and detect a nucleic acid which 30 generally always occurs in a body fluid. Examples of suitable nucleic acids are the mRNA coding for β -globin or for glyceraldehyde-phosphate dehydrogenase (GAPDH) (see, for example, GB 2 260 811) which always occur in the cells of the body fluid. Suitable oligonucleotide 35 primers for human β -globin mRNA are, for example, primers with the sequences:

5' ACCCAGAGGT TCTTGAGTC 3' (Glob 1) and
5' TCTGATAGGC AGCCTGCACT 3' (Glob 2)

Further internal positive controls of the method and of the sample to be investigated can additionally be cell-specific nucleic acids, such as
5 β -actin mRNA, with the primers (Nakajima-Iiji, S., Hamada, H., Reddy, P., Kakanuga, T. (1985): Molecular structure of the cytoplasmatic β -actin gene: Interspecies homology of sequences in the introns. Proc Natl Acad Sci USA 82, 6133-7):

10

5' GATGATGATATGCCCGCGCTCGTC 3' (Act 1)
5' CTCAAACATGATCTGGGTCACTTTC 3' (Act 2)

or T-cell-specific nucleic acids, such as the mRNA of
15 the T-cell receptor, with the primers (Toyonaga, B., Yoshikai, Y., Vadasz, V., Chin, B., Mak, T.W. (1985): Organization and sequences of the diversity, joining, and constant region of the human T-cell receptor β chain. Proc Natl Acad Sci USA 82, 8624-8):

20

5' GAGGTCGCTGTGTTGAGCCATCAGAAG 3' (TCR 1)
5' GATCTCATAGAGGATGGTGGCAGACAG 3' (TCR 2)

To prevent or reduce false-positive results or
25 so-called background noise which is caused by telomerase activities which are possibly present in nontumor cells, the sample to be investigated is, according to the invention, initially subjected to a process for enrichment or depletion of tumor cells. To
30 this end, it is advantageous to either purify the body fluid sampled, by appropriate methods or to cultivate it under conditions which are unfavorable for the contaminating telomerase-positive nontumor cells but favorable for the tumor cells present.

35 In the case of purification, in particular from the sample to be investigated, stem cells and/or activated immune cells should be depleted or tumor cells concentrated. Since, in general, the individual cells have specific surface markers, removal or

concentration of the cells by immunoabsorption is particularly advantageous. Examples of suitable methods are magnetic (MACS) or fluorescence-activated (FACS) cell sorting [see, for example, B. Göttlinger & 5 Radbruch (1993) mta, 8, 530-536, No. 5]. Thus, for example hematopoietic stem cells can be removed from the blood sample by means of MACS via their CD34 surface marker [Kato & Radbruch (1993) Cytometry, 14, 384-392]. B cells can be removed, for example, via their CD10, 10 CD19 and/or CD20 surface markers, and T cells via CD45RA and/or CD7. Tumor cells can be concentrated via their specific tumor markers, for example CEA. Besides MACS or FACS, also particularly suitable for depletion or concentration of the relevant cells are antibodies 15 against the specific surface markers, which are bound in particular to commercially available magnetic beads (for example Dynabeads M450, Dynal Corp.).

Mononuclear cells can be isolated by the following methods:

20 specific lyses of the erythrocytes (for example ammonium chloride/hypertonic shock),
specific lyses of mononuclear blood cells (for example L-leucyl-L-leucine methyl ester for monocytes and cytotoxic cells),
25 negative/positive selection via specific surface markers (for example negative: CD 4, 8, 34, etc.; positive: Ber-EP4, AUA1, CEA),
density gradient centrifugation of euploid vs.
aneuploid cells or
30 density gradient centrifugation of mononuclear annuclear cells (for example Ficoll).

In the 60s and 70s, when methods such as, for example, FACS or MACS were still unavailable, tumor cells of hematopoietic cells were separated based on 35 their differing density (J.A. Fleming et al., J. clin. Path. (1967), 20, 145). According to this data, tumor cells have a specific density of 1.040-1.080, whereas erythrocytes and polymorphnuclear leukocytes have a higher density. In contrast, lymphocytes have a

specific density in the range from 1.060-1.075, thus overlapping with the specific density of tumor cells. Thus, complete removal of the likewise telomerase-active lymphocytes from the tumor cells via their 5 differing densities should not be possible. Consequently, use of a standard solution for isolating lymphocytes, such as, for example, Histoprep® of a density of 1.077 g/ml showed that lymphocytes of healthy blood donors of a density of up to 1.077 g/ml 10 have telomerase activity.

For a particularly preferred embodiment of the method according to the invention, it has now been found that the tumor cells can be concentrated by covering a cell separation medium of a density in the 15 range from 1.055 to < 1.070 g/ml with a layer of the body fluid which contains the tumor cells, followed by centrifugation. By using the specific cell separation medium, the cells which are present in the body fluid are separated such that the lymphocytes which are, 20 owing to their density, concentrated together with the tumor cells have no telomerase activity.

In the concentration process, a cell separation medium is used as discontinuous gradient, which is covered with a layer of the body fluid. By 25 centrifugation, the cells are separated according to their specific cell density and can be collected in individual fractions. The specific density of the cell separation medium permits virtually complete separation of tumor cells from the corpuscular fractions present 30 in body fluids, specifically from the cells of the red and white blood system. In addition, the method permits the separation of telomerase-positive from telomerase-negative hematopoietic cells, where the concentrated tumor cells are, after centrifugation, in the same 35 fraction as the telomerase-negative hematopoietic cells, so that a subsequently detected telomerase expression in this fraction can be assigned without any doubt to the tumor cells present.

DEININGER

It is also surprising that the reduction of the density of the cell separation medium, which is slight compared with the prior art, permits the number of contaminating blood cells to be reduced considerably.

5 As a consequence, the total cell count is reduced significantly without any significant loss of tumor cells, which makes, for example, screening of microscopic preparations considerably easier and, on a clinical scale, possible in the first place.

10 It has been found that a particularly good separation performance is achieved using a cell separation medium of a density in the range from 1.060-1.067 g/ml, more preferably 1.060-1.065 g/ml and particularly preferably about 1.065 g/ml.

15 The centrifugation is advantageously carried out at about $1000 \times g$ for about 30 minutes. The temperature during the centrifugation is preferably about 4°C. It has been found to be particularly advantageous to carry out the centrifugation using slow 20 acceleration and no braking, so that the cell separation medium and the body fluid at the beginning of the centrifugation or the fractions at the end of the centrifugation are not mixed with one another.

The cell separation medium used can, in 25 principle, be any suitable liquid of the desired density. The cell separation medium should not react with the body fluid or the cells contained therein. Advantageously, use can be made of, for example, Ficoll or Percoll, where the solutions are adjusted to the 30 desired density, in each case following the instructions of the manufacturer. The amount of the Percoll stock solution to be diluted, having a density of 1.13 g/ml, which is required for preparing 100 ml of a Percoll work solution of the desired density (dd) is 35 calculated, for example, according to the formula:

$$100 \text{ ml} \times (\text{dd} - 1.13 - 0.9) / 0.13.$$

In each case, 10% of the Percoll work solution of the desired density consists of a 1.5 M NaCl solution, to ensure physiologic osmolarity. The difference between the amount of Percoll stock solution 5 (density 1.13 g/ml) calculated using the above formula and the salt solution is then filled up with water to give 100 ml.

Thus, a Percoll work solution of a density of 1.060 g/ml can be prepared, for example, as follows:

10

41.54 ml of the Percoll stock solution (density of 1.13 g/ml)

48.46 ml of H₂O

10.00 ml of 1.5 M NaCl

15

100.00 ml of Percoll work solution, dd 1.060 g/ml

The densities stated are based on a temperature of 20°C. The work solutions are advantageously prepared 20 at room temperature and checked, for example with the aid of marker beads of a defined density.

If the body fluid used is peripheral blood, this is advantageously drawn in an anticoagulant substance and, before covering the layer of cell 25 separation medium, diluted with a diluent. Preferred anticoagulant substances are EDTA or citrate; a suitable diluent is, for example, PBS. The blood is preferably diluted in a ratio of about 1:1. Suitable peripheral blood is venous or arterial blood.

30

For concentrating the tumor cells, the body fluid to be investigated is collected or drawn in accordance with customary standard protocols. Depending on the type of body fluid, it is then either initially diluted with a diluent, preferably a buffer, or it is 35 used directly, undiluted to cover the layer of cell separation medium in a centrifugation vessel. Alternatively, it is possible to centrifuge the body fluid beforehand at, for example, 1000 x g for about 10 min and, after resuspending the cells in a buffer,

to cover the layer of cell separation medium. The preferred buffer is Dulbecco PBS. A suitable centrifugation vessel is, in particular, a siliconized centrifugation vessel, preferably of plastic, having a 5 capacity of, for example, 1-500 ml. It should be possible to close the centrifugation vessel.

In a further preferred embodiment of the concentration method, one or more substances which inhibit aggregation of platelets with tumor cells are 10 added to the body fluid prior to covering the cell separation medium. These substances can be added, for example, together with the buffer used as diluent. Suitable substances for preventing an undesirable aggregation of platelets with tumor cells are, for 15 example, EDTA, citrate and ACD-A (acid citrate dextrose). Additionally or alternatively, the body fluid can be freed, before the cell separation medium is covered, from substances which promote aggregation of platelets with tumor cells. These are, for example, 20 ions, such as magnesium and calcium ions.

In the centrifugation vessel, the cell separation medium, having a higher density than the body fluid to be investigated, is initially charged and subsequently covered with the body fluid. Depending on 25 the dimensions of the centrifugation vessel and the volume of the body liquid from which the tumor cells are to be concentrated, the volume of the cell separation medium to be charged initially can be, for example, 1-250 ml.

30 It has been found to be particularly advantageous to cool the lower quarter of the centrifugation vessel after centrifugation and before the interphase enriched with tumor cells is drawn off intensively for a short period of time to prevent cell 35 contamination. For example, erythrocytes and leukocytes which are present in the cell pellet can be immobilized by cooling the lower quarter of the centrifugation vessel intensively in liquid nitrogen for 5-10 minutes. Here, interphase refers to the transition between the

cell separation medium and the supernatant body fluid. The tumor cells are concentrated in this interphase and, after centrifugation, collected, for example by siphoning off this phase. The intensive cooling of the 5 centrifugation vessel prevents mixing of the cells from the different phases, which excludes false-positive test results.

To ensure that the operations proceed as smoothly as possible, the centrifugation can be carried 10 out in a vessel which is divided into an upper and a lower compartment by a porous barrier, a filter or a sieve, hereinbelow referred to as porous barrier or barrier, where the cell suspension medium is initially charged in the lower compartment and the body fluid is 15 introduced into the upper compartment. This prevents mixing of the body fluid to be investigated, in the upper compartment, with the cell separation medium, in the lower compartment, before and after the centrifugation step.

20 The position of the porous barrier in the centrifugation vessel can be chosen such that the fluid level of the cell separation medium is either exactly below, exactly within or exactly above the porous barrier.

25 The porous barrier can, for example, have a thickness of 1-10 mm, preferably about 5 mm. In addition, the porous barrier should be strong enough to resist the centrifugation forces without suffering any damage.

30 Preference is given to using barriers having a porous nature which is such that, during centrifugation, liquid and the corpuscular components of blood, such as the cells of the red and white blood system, but not the tumor cells, can pass the porous 35 barrier unhindered. As a consequence, the cell separation medium is, during centrifugation, forced through the porous membrane into the upper compartment and the tumor cells and platelets come to rest on a level above the barrier. Particularly suitable for this

purpose are porous barriers having a pore size of 20-100 μm , preferably 20-30 μm .

The porous barrier can be of any suitable material. Suitable materials are, for example, plastic, 5 metal, ceramic or a mixture or special alloy of these substances. However, it is also possible to use any other natural or synthetic suitable material.

In a further preferred embodiment, the porous barrier is made of a hydrophobic material or is coated 10 with a hydrophobic material.

With the aid of the porous barrier, the body fluid to be investigated can be filled into the centrifugation vessel without any mixing with the cell separation medium below which might negatively affect 15 or prevent the concentration.

After the centrifugation, the tumor cells present in the body fluid are in the interphase of the upper compartment of the centrifugation vessel. About 20 80% of the fluid above the interphase can then be siphoned off carefully and discarded. If, for example, the body fluid used is blood, this residual fluid is a plasma/PBS mixture which contains the serum proteins. The remaining supernatant above the barrier, which 25 contains the tumor cells, can then be collected and, for example, transferred into a fresh centrifugation vessel (preferably made of siliconized plastic and having the same capacity by volume as the centrifugation vessel used beforehand). When the remaining supernatant is removed, the porous barrier 30 prevents any mixing of the cells of the upper and the lower compartment.

Advantageously, the upper compartment of the centrifugation vessel is then, for example, washed twice with a buffer, and this is likewise transferred 35 into the fresh centrifugation vessel. Suitable buffers are, for example, Dulbeccos PBS (3.9 mM EDTA, pH 8.0, without calcium and magnesium) or NaCl/10% ACD-A (Guidelines for the collection, processing and storage of human bone marrow and peripheral stem cells for

transplantation, prepared by the BCSH Blood Transufusion Task. Transfus. Med. 1994; 4: 165-72) or NaCl/5% ACD-A/1% albumin). After a further centrifugation, for example, at $1000 \times g$ at a temperature of about 4°C for 5 about 10 min, the collected cells can be subjected, for example, to the tumor cell detection methods.

To render the cell ring at the interphase between cell separation medium and body fluid, which is obtained after the centrifugation and which contains 10 the tumor cells, more visible for removal from the centrifugation vessel, it has been found to be advantageous to add a dye to the cell separation medium. It is possible to add, for example, 80 μl of a 15 5% Trypan Blue solution to 100 ml of a Percoll work solution.

However, if a centrifugation vessel having a porous barrier is used, once the supernatant residual fluid above the interphase has been removed, preference 20 is given to remove not only the interphase but the entire residual fluid above the porous barrier, not only because there are further cells between interphase and porous barrier but also because the cells present 25 in the cell ring can easily be mixed by removal. To avoid losing cells from the upper compartment, this is advantageously washed twice with buffer (for example PBS).

With the concentration step, it is possible to concentrate circulating tumor cells and in particular circulating tumor cells of solid tumors, i.e. non-hematological tumors, or hematological tumor cells, 30 i.e. tumor cells of the red and white blood system.

Using the concentration method, tumor cells can, owing to their differing density, be separated virtually completely from the corpuscular components of 35 body fluids, such as, for example, the cells of the red and white blood system, be concentrated and then subjected to the next step of the quantification method according to the invention.

The concentration method described has the advantage that telomerase-positive hematopoietic cells can be removed in a simple and safe manner from the tumor cells to be concentrated, so that, in the 5 subsequent quantification step, no false-positive results by telomerase-active nontumor cells are obtained. In addition, the concentration and isolation of the tumor cells from body tissue requires only a few operations, thus making possible processing of 10 relatively large amounts of sample material. Compared to, for example, the use of specific antibodies and subsequent separation by suitable apparatus, the costs for the materials required are significantly lower.

In addition, investigation of 10 different cell 15 lines derived from tumor tissue, such as melanoma, prostate, breast, lung, liver and colorectal carcinoma, showed that the cells of all these cell lines are, in their majority, concentrated by the concentration process described.

20 In an alternative procedure for separating the blood cells in Ficoll or Percoll, the cells contained in the sample can be cultivated under conditions which are unfavorable for the contaminating telomerase-positive nontumor cells but favorable for the tumor 25 cells present. The result of this cultivation method is that contaminating telomerase-positive nontumor cells die, whereas the tumor cells present survive.

To this end, for optimizing the cell culture, to favor, on the one hand, the proliferation of the 30 tumor cells and, on the other hand, blood cells entering the G₀/G₁ phase, or their apoptosis, to concentrate metastasizing tumor cells present, the sample can be subjected to the following conditions: selection of suitable culture media using (autologous) 35 sera,
duration of cultivation,
selection of optimum oxygen/carbon dioxide content,
addition of tumor cell/epithelial cell specific growth factors (for example EGF etc.) or

selection of a suitable surface coating to increase adherence of the tumor cells in cell culture containers and selection of adherent cells over suspended cells.

Thus, for example, cultivation can be carried out as follows:

All or aliquots (for example on microtiter plates) of the cells contained in the sample can be cultured with or without additives. Subsequently, these cultures can be subjected to influences under which nontumor cells die, but tumor cells survive. These influences can, for example, be simply the duration of the cultivation, internal (for example increase or decrease of the pH in the culture medium) or external influences (such as, for example, increase or decrease of pCO_2 or pO_2). Our investigations have shown, for example, that even during a simple cultivation of whole blood at 37°C for 5 days the mRNA coding for the catalytic subunit of human telomerase (hTRT) was no longer detectable between day 1 and day 2. However, the mRNA for the T cell receptor (TCR) (3 days) and β -actin (5 days) was still detectable (see Fig. 4).

In addition, cultivation by the abovementioned methods of nontumor cells and tumor cells contained in the fluids can be carried out both before and after separation of the cells from the body fluid (for example after gradient centrifugation with, for example, Fiquoll-Hypaque).

It is also particularly advantageous, alone or in conjunction with the purification or cultivation methods described above, to compare the amount of mRNA which codes for the catalytic subunit of telomerase from venous blood with the amount of mRNA which codes for the catalytic subunit of telomerase from arterial blood, since it is possible to detect, for the purpose of tumor cell determination, only about 20% of all cells in venous blood samples, compared with 100% of the cells in arterial blood samples [Koop, S. et al. (1995) Cancer Res. 55, 2520-2523]. It is likewise

suitable to compare blood from the finger pad with venous or arterial blood.

Quantitative determination of the mRNA which codes for the catalytic subunit of telomerase in the sample makes it possible to determine whether tumor cells, especially metastases, in particular micrometastases, of malignant tumors are present in the body fluid, and in what quantity. This is of great use in particular for early clinical diagnosis of the formation of metastases from malignant tumors and for monitoring tumor therapy. Tumor cells which can be detected with the present invention are, in particular, tumor cells from metastases, preferably micrometastases, from malignant tumors, especially cells from metastasizing tumors and/or neoplasms which are derived, for example, from a T-cell lymphoblastoma, T-cell leukemia cells, chronic myeloid leukemia cells, acute lymphatic leukemia cells, chronic lymphatic leukemia cells, teratocarcinoma, melanoma, carcinoma of the lung, large bowel cancer, breast cancer, hepatocellular carcinoma, kidney tumor, adrenal tumor, prostate carcinoma, neuroblastoma, brain tumor, small-cell carcinoma of the lung, rhabdomyosarcoma, leiomyosarcoma and/or lymphoma.

The present invention further relates to the oligonucleotide primers with the sequence

5' CTACCGGAAG AGTGTCTGGA GCAAGTTGCA AAGC 3' (hTRT1)

and/or

30 5' GGCATACCGA CGCACCGCAGT ACGTGTTCTG 3' (hTRT2),

where hTRT1 and/or hTRT2 may, where appropriate, additionally comprise a promoter sequence for an RNA polymerase;

35

and an oligonucleotide with the sequence

5' CGTTCTGGCT CCCACGACGT AGTC 3' (hTRT o)

and the corresponding reverse complementary sequences of the oligonucleotide for detecting the amplified "antisense" RNA.

The invention additionally relates to a kit for quantifying tumor cells in a body fluid, for example blood, urine or else stool, exudates or transudates from body cavities, especially peripheral blood, comprising

(a) oligonucleotide primer pair for specific amplification of telomerase-encoding nucleic acid, where the oligonucleotide primer pair preferably has the following sequences:

5' CTACCGGAAG AGTGTCTGGA GCAAGTTGCA AAGC 3' (hTRT1)

and/or

5' GGCATACCGA CGCACGCAGT ACGTGTTCTG 3' (hTRT2),

where hTRT1 and/or hTRT2 may, where appropriate, additionally comprise a promoter sequence for an RNA polymerase.

In a further embodiment, the kit according to the invention additionally comprises (b) a nucleic acid or nucleic acids for co-amplification, preferably 3 RNA standard nucleic acids for co-amplification.

The novel kit may also comprise in addition, as described in detail above, a labeled oligonucleotide as hybridization probe for specific detection of the amplified cDNA of the wild-type sequence and/or several labeled oligonucleotides as hybridization probe for specific detection of the amplified cDNA of the standard nucleic acid or nucleic acids. In addition, a novel kit for PCR amplification may additionally comprise the enzymes described in detail above, where appropriate labeled nucleotides and/or suitable buffers, such as, for example, a reverse transcriptase, preferably an AMV reverse transcriptase, a DNA polymerase, preferably a Taq polymerase and/or a DNase and, where appropriate, means suitable for depletion of stem cells and/or activated immune cells and/or for

concentration of tumor cells, as described in detail above.

Another novel kit for NASBA amplification [sic] may likewise comprise, besides the standard nucleic acids described in detail above, a labeled oligonucleotide as hybridization probe for specific detection of the amplified "antisense" RNA of the wild-type sequence and/or several labeled oligonucleotides as hybridization probe for specific detection of the amplified "antisense" RNA of the standard nucleic acid or nucleic acids. It may additionally likewise comprise the enzymes described in detail above, where appropriate labeled nucleotides and/or suitable buffers, such as, for example, a reverse transcriptase, preferably an AMV reverse transcriptase, an RNA polymerase, preferably a T7 RNA polymerase, an RNase H and/or a DNase, and, where appropriate, means suitable for depletion of stem cells and/or activated immune cells and/or for concentration of tumor cells, as described in detail above.

The following examples and figures are intended to describe the present invention in detail without, however, restricting it thereto.

25 Description of the figures

Fig. 1 shows the sequence described by Nakamura et al., encoding the catalytic subunit of human telomerase, of 4015 base pairs (bp), and the position of the designed oligonucleotide primers or the oligonucleotide probe (hTRT o) (underlined): 5' primer hTRT1 (position 1780-1813), 3' primer hTRT2 (position 2261-2290) with an amplification product of 513 base pairs (bp) and the probe hTRT o (position 1964-1987).

35 Fig. 2 shows (A) a diagram of the genomic organization of human telomerase (hTRT). The telomerase protein has a telomerase-specific region (T, labeled black) and has homologies to conserved regions of the reverse transcriptases of different viruses (1, 2 and A

to E, hatched). The primer pair used (hTRT1, hTRT2) is indicated by arrows and is localized in a region which does not have any homologies with viral reverse transcriptases. (B) shows an agarose gel electrophoresis of an RT-PCR amplification with hTRT-specific primers on RNA of the human teratocarcinoma cell line Tera2. Band M: marker, band 1 RT-PCR amplification, band 2: the corresponding DNA control without reverse transcriptase reaction.

Fig. 3 shows an agarose gel electrophoresis (a) of the RT-PCR products with TCT-specific primers on RNA and DNA of human PBMC and the human fibroblast cell line MRC5 and the corresponding Southern blot analysis with a TCR-specific oligonucleotide probe (TCT probe). M: marker.

Fig. 4 shows an agarose gel electrophoresis of the RT-PCR products with specific primers for hTRT (A) and TCR and actin (B) on RNA which had been isolated from 1 ml of whole blood, after cultivation for 0-5 days, and a reaction on the RNA of the human teratocarcinoma cell line Tera2. Bands 0^d-5^d: culture period of 0 to 5 days, respectively. M: marker, Tera2: human teratocarcinoma cell line Tera2.

Fig. 5 shows an agarose gel electrophoresis of the RT-PCR products on RNA of the prostate carcinoma cell line LNCap. Bands 10³-10⁻²: number of cells used per experiment. DNA: DNA control. H₂O: water control. M: marker. As shown in Fig. 7, the PCR was carried out using specific primers (Fig. 6) for the catalytic subunit of human telomerase (A) and β -actin, for 40 cycles. Under the RT-PCR conditions described, the mRNA coding for the catalytic subunit of human telomerase can be demonstrated in up to 10 cells (arrow). To exclude DNA contaminations, RNA from 10³ cells without reverse transcriptase as control reaction and a water control (H₂O) were also tested in the RT-PCR.

Fig. 6 shows the sequences of the oligonucleotides used here.

Fig. 7 shows a flow chart for the method according to the invention.

Fig. 8 shows the result of an RT-PCR analysis of blood of a healthy donor (A) and blood of the same 5 donor mixed with GFP-transfected cells of the melanoma cell line T289 (B, C) after tumor cell concentration using a cell separation medium of a density of 1.070 g/ml.

Fig. 9 shows the result of an RT-PCR analysis 10 of blood of healthy donors which had been mixed with tumor cells of a prostate carcinoma (A) and mamma carcinoma cell line (B), after tumor cell concentration using a cell separation medium of a density of 1.065 g/ml.

Fig. 10 shows the recovery rate of GFP-transfected melanoma cells which were mixed into blood 15 of different (A, B) healthy donors, after a concentration using a cell separation medium of a density of 1.065 g/ml.

20

EXAMPLES

Unless noted otherwise, the following examples 25 were carried out by standard methods as described, for example, by Sambrook, J. et al. (1989) *supra*, or in accordance with the instructions of the manufacturers of the kits and enzymes used.

1. Tumor cell concentration

30

1.1 General procedure

In a siliconized centrifugation vessel made of plastic, venous blood (5-20 ml) was admixed with EDTA 35 (final concentration 3.9 mM, pH 8.0) and mixed with 1 volume of PBS. The blood/PBS mixture was then applied to 5-10 ml of Percoll of a density of 1.065 g/ml and, with slow acceleration and without brake, centrifuged at 1000 \times g and 4°C for 30 min. The lower quarter of

the centrifugation vessel was subsequently incubated in liquid nitrogen for 5-10 min. This prevented contamination with cells of the pellet during the siphoning off of the cells which were located on the 5 interphase in the transition between the Percoll and the supernatant plasma/PBS mixture. The cells of the interphase, which were mainly platelets and tumor cells circulating in the blood, were then transferred into a new siliconized centrifugation vessel made of plastic 10 and centrifuged at $1000 \times g$ and $4^\circ C$ for 10 min. For the RT-PCR investigation that followed, the cell platelet was taken up in a guanidinium isothiocyanate buffer, as a result of which the cells were lysed and could be subjected to RNA isolation.

15

1.2 Spiking experiment

Using so-called spiking experiments, where the tumor cells of different cell lines are mixed with the 20 blood of normal donors and the tumor cells are subsequently reisolated and investigated in the RT-PCR, it was shown that, depending on the cell line used, the telomerase activity of about 1-4 spiked tumor cells/ml of blood can be detected.

25

To this end, the cells of the tumor cell lines to be spiked were cultivated to confluence according to the instructions of the manufacturer (ATCC, American Tissue Cell Culture). The cells were then tryptanized and washed in medium (RPMI 1640). A $10 \mu l$ aliquot was 30 removed and mixed 1:1 with Tryptan Blue, and the living cells were then determined in a counter and the corresponding cell concentration was calculated. The cell suspension was then diluted and a volume corresponding to a certain cell count was mixed with 35 blood of healthy blood donors. Blood without any added tumor cells was used as control. The spiked tumor cells were concentrated once, for comparison, with a cell separation medium of a density of 1.070 g/ml, and according to the inventive method. To determine the

recovery rate, microscopic, flow-cytometric and RT-PCR analyses were then carried out.

a) Comparative experiment

5

Fig. 8 shows the result of an RT-PCR analysis of 20 ml of blood of a healthy donor (A) and 20 ml of blood of the same donor mixed with GFP-transfected cells of the melanoma cell line T289 (B, C). The blood 10 was supplied as upper layer onto Percoll of a density of 1.070 g/ml and centrifuged, and the cells were then analyzed. In normal blood, the catalytic subunit of telomerase (hTRT) cannot be detected (A), whereas hTRT 15 is detectable in the case of 1 and 2 spiked melanoma cells per ml of blood (B, C). However, at the Percoll density of 1.070 g/ml used, there is still a sufficiently high number of telomerase-active leukocytes in the interphase, so that the RNA component (hTR) can be detected even in unspiked blood. The 20 presence of activated and, as a consequence, probably also telomerase-active leukocytes in the fraction of the isolated cells is also confirmed by the fact that CD69, an early activation marker in B and T cells, can be detected in all blood samples (A-C). The tumor 25 marker CEA (Carcinoembryonic Antigen) is negative both in unspiked and in spiked blood (A-C). GFP (Green Fluorescent Protein), which was used as additional marker for the spiked tumor cells, cannot be detected in unspiked blood (A). Since only about 50% of the 30 transfected T289 melanoma cells express GFP, the protein can only be detected in up to 2 spiked tumor cells per ml of blood (B). Actin served as RT-PCR positive control (actin) and, in the experiment without 35 RT reaction, as negative control (actin ØRT). The PCR amplification of genomic DNA of untransfected T289 cells with the specific primer pairs for hTRT, GFP and CD69 does not give rise to any amplification products.

b) Experiment according to the invention

Fig. 9 shows RT-PCR analyses of the blood of healthy donors which had been mixed with tumor cells of a prostate carcinoma (A) and mamma carcinoma cell line (B), applied as upper layer onto Percoll of a density of 1.065 g/ml, centrifuged and then analyzed. In contrast to when Percoll of a density of 1.070 g/ml was used, the RNA component of the telomerase (hTR) can not be detected in the unspiked blood (cf. Fig. 1). hTR can be detected in the samples with 2 spiked prostate carcinoma cells (A) and with 4 spiked mamma carcinoma cells (B) per ml of blood (black arrow). In contrast to the melanoma cell line T289, an expression of the catalytic subunit (hTRT) could not (A) be detected in these tumor cells, or only at 10^4 tumor cells (B). Neither the prostate-cell-specific marker PSA (Prostate Specific Antigene) nor the epithelial-cell-specific marker CK20 (Cytokeratin 20) can be detected in the corresponding tumor cells. Actin is used as RT-PCR positive control.

Fig. 10 shows the recovery rates of GFP-transfected melanoma cells (T289) which had been admixed with blood samples of healthy donors (spiked). The spiked blood samples were then applied as a layer onto Percoll of a density of 1.065 g/ml and centrifuged, and the number of reisolated tumor cells (recovery) was determined microscopically (-●-) and/or by flow cytometry (-▲-). Since only about 75% and 50% of the GFP-transfected T289 cells could be detected in the flow cytometer for sample A and sample B, respectively, the recovery rates were corrected correspondingly. The recovery rate of spiked tumor cells depends on the blood donor in question (the blood samples of A) and B) originate from different donors) and the cell line used and is inversely proportional to the number of spiked tumor cells. It is possible for a rejection reaction of the corresponding hematopoietic cells to lead to lysis, aggregation and finally loss of

the spiked allogenic tumor cells. In addition, B) shows that the number of the actual spiked tumor cells (-■-) is 6%-37% lower than the theoretical number of spiked tumor cells (-◆-).

5 Taking into account investigations with lung and mamma carcinoma cells, not shown here, an average recovery rate with the concentration method preferred according to the invention is $46\% \pm 20\%$ for 4-512 spiked cells (n=16) and $54\% \pm 20\%$ (n=15) for ≤ 50 10 spiked cells.

The recovery rate of the tumor cell concentration method which is preferred according to the invention is thus approximately in the range of magnetic cell separators such as MACS, for which the 15 stated recovery rate is about 30-58%.

2. Cultivation and isolation of peripheral blood, tissue and cells for the examples below

20 Tumor cell lines such as the human prostate carcinoma cell line LNCap and the teratocarcinoma cell line Tera 2 were cultured as recommended by the ATCC (American Tissue Culture Collection). Venous blood donated by healthy control subjects was taken by 25 puncture of a forearm vein in EDTA monovets® (Saarsted).

3. Isolation of cellular RNA

30 Total cellular RNA was isolated by standard methods [Chomczynski et al. (1987) Anal Biochem 162, 156; Sambrook, J. et al. (1989). Cold Spring Harbor, New York, USA, Cold Spring Harbor Laboratory Press]. Peripheral blood was transferred and homogenized, as shown in Fig. 7, immediately after removal into RNA 35 lysis buffer (4 M guanidinium isothiocyanate; 0.1 M Tris-HCl, pH 7.5; 1% mercaptoethanol). The mixtures were either immediately processed further or stored at -70°C.

4. Reverse transcription and polymerase chain reaction
(RT-PCR)

The RT-PCR was carried out, as shown in Fig. 7, with the GeneAmp® RNA-PCR kit (Perkin Elmer) as specified by the manufacturer. Aliquots of the isolated total RNA from peripheral blood and cell lines were in each case previously hydrolyzed with 4U of DNase and 40U of RNase inhibitor (Boehringer, Mannheim) in 36 µl mixtures (in 100 mM Tris-HCl, pH 8.3; 50 mM KCl; 5 mM MgCl₂, 1 mM dNTP mix and 2.5 mM random hexamers) at 37°C for 30 minutes and then at 75°C for 10 minutes and then the DNase was inactivated at 90°C for 10 minutes and the reaction mixture was immediately stored in ice.

The two oligonucleotide primers:

15 5' CTACCGGAAG AGTGTCTGGA GCAAGTTGCA AAGC 3' (hTRT1) and
5' GGCATACCGA CGCACGCAGT ACGTGTTCTG 3' (hTRT2)

20 were designed in accordance with the sequence, published by Nakamura et al., coding for the catalytic subunit of human telomerase (Nakamura et al. (1997). Science 277: 955-9) (Fig. 1) and synthesized using an Applied Biosystem 380A synthesizer. The specificity of the hTRT1 and hTRT2 primers was checked by computer-assisted analysis of homology on the nucleic acid sequences in the GenBank, EMBL, DDBJ and PDB databases using BLASTN 1.4.9 MP [Altschul, S. F. et al. (1990), J Mol Biol 215: 403-410].

30 For consistency of the amplified amounts, the same amounts of RNA were employed for the RT reaction in each experiment. In order to preclude contamination of the RNA preparations with genomic DNA, each RNA-containing sample hydrolyzed with DNase was first subjected to the PCR described below and checked for 35 amplification. The RNA-containing sample in which no amplification product was detectable was employed for the subsequent cDNA synthesis and PCR steps. Oligonucleotide primers for β-actin and TCR were employed as internal standard control (Fig. 6). The

reverse transcriptase reaction was carried out using 18 μ l of the DNase digest, with addition of 50 U MuLV reverse transcriptase and 40U RNase inhibitor, at 42°C for 30 minutes, and the reaction was terminated at 99°C 5 for 5 minutes. In the negative controls, 40 μ l of water were added instead of the enzymes.

The PCR was carried out, as shown in Fig. 7, on 5 μ l of the cDNA reaction using the following program: (97°C: 15 seconds, preheating); (97°C: 15 seconds, 10 70°C: 30 seconds [minus 0.5°C per cycle], 72°C: 30 seconds) 10 cycles; (94°C: 15 seconds, 65°C: 30 seconds [minus 0.5°C per cycle], 72°C: 30 seconds) 20 cycles; (94°C: 15 seconds, 50°C: 30 seconds, 72°C: 30 seconds [plus 15 seconds extension per cycle], 15 10 cycles; (72°C: 7 minutes, final extension).

The amplification products were fractionated by gel electrophoresis on 1.5% TAE agarose gel, stained with ethidium bromide and visualized and recorded by photography under UV light (see Figs. 2-5).

20 5. Preparation of possible standard RNA nucleic acids (hTRTKa, hTRTKb and hTRTKc)

The PCR amplification products intended for cloning can be fractionated by gel electrophoresis on 25 1.5% TAE agarose and eluted (Qiagen). The restriction hydrolysates can be purified by phenol/chloroform extraction and precipitated in salt and ethanol or by DNA purification (Qiagen). The constructs can be created, for example, by ligating the fragments into 30 the corresponding cleavage sites in a cloning and transcription vector, for example pGEM-13zf(+), using T4 ligase. This vector permits *in vitro* transcription of cloned fragments by use of Sp6 or T7 RNA polymerases as selected. Competent bacteria (XL-1Blue, Stratagene) 35 are transformed by electroporation (BioRad). Plasmid DNA is purified using plasmid purification kits (Qiagen). Positive clones are validated using vector- or sequence-specific oligonucleotide primers with the

PCR. Sequence validation can be carried out for the constructs by semiautomatic sequence analysis.

The construct pGEM-hTRT is created as initial construct for the constructs pGEM-hTRT(Ka), pGEM-hTRT(Kb) and pGEM-hTRT(Kc). pGEM-hTRT(Ka) pGEM-hTRT(Kb) and pGEM-hTRT(Kc) differ from pGEM-hTRT and from one another by a randomized exchange of sequence of about 20 base pairs (bp). The constructs are used for in vitro transcription with Sp6 RNA polymerase of the standard RNA: hTRT(Ka), hTRT(Kb) and hTRT(Kc). To form the construct pGEM-hTRT, the cDNA of the catalytic subunit of human telomerase (Fig. 1) is cloned, for example, into the NotI and HindIII cleavage sites of pGEM-13Zf(+). This is achieved by carrying out an RT-PCR with these cleavage-site-containing oligonucleotide primers, which are derived from the sequence hTRT (Fig. 1), on the previously isolated RNA from tumor cells or lines under the conditions described above. Thus, it is possible, for example, to amplify the full-length hTRT with given cleavage sites, or a shorter fragment. After a restriction hydrolysis with specific restriction enzymes, for example NotI and HindIII, the fragment formed is cloned into the corresponding cleavage sites (for example position 12 or 38) of pGEM-13Zf(+) and the construct pGEM-hTRT is created. pGEM-hTRT(Ka) is constructed by replacing an about 20bp sequence in the construct pGEM-hTRT by an about 20bp cassette. This replacement is carried out by recombinant PCR and is a modification of the method described by Higuchi et al. [Higuchi, R. (1988). Nucleic Acid Res 16: 7351-7367; Higuchi, R. (1990). M. Innis A. et al. Eds. San Diego, New York, Berkley, Boston, London, Sydney, Tokyo, Toronto, Academic Press, Inc. 177-183]. In a first step, two independent PCR reactions are carried out on pGEM-hTRT: the amplification product from the 1st PCR gives the 5' fragment and is digested with suitable restriction enzymes to give a 5' fragment. The amplification product from the 2nd PCR reaction gives the 3' fragment

and is hydrolyzed with suitable restriction enzymes to give a 3' fragment. Using T4 ligase, the cleavage sites of the 5' and 3' fragments are connected to give a fragment which is cloned into the corresponding 5 cleavage sites of pGEM-13Zf(+), to create the construct pGEM-hTRT(Ka). pGEM-hTRT(Kb) and pGEM-hTRT(Kc) are constructed by replacing the about 20bp sequence, created above, in the construct pGEM-hTRT(Ka), in each case with a randomized sequence of about 20bp. RNA can 10 then be produced in vitro from pGEM-hTRT(Ka), pGEM-hTRT(Kb) and pGEM-hTRT(Kc) with Sp6 RNA polymerase. The specific RNAs can then be detected with oligonucleotides O(Ka), O(Kb), O(Kc) and W(wt), which are complementary to the abovementioned about 20bp 15 replacement sequences and to the wild-type sequence (wt), respectively. The further processing of the RNA, such as DNase digestion, purification and calibration, is carried out by standard methods.

20 6. Results

The investigations on tumor cell lines revealed that the mRNA which codes for the catalytic subunit of human telomerase was detectable in different amounts in tumor cell lines with the same amount amplified in the 25 TCR or β -actin control reaction (Fig. 2, 4 and 5). It was possible to rule out contamination with genomic DNA in each case by a control reaction without addition of reverse transcriptase.

In comparative investigations, using whole- 30 blood cultivations of different durations, it was shown unambiguously that, after cultivation of the whole blood for 1-5 days, no more specific RT-PCR product of the catalytic subunit of human telomerase could be detected. In parallel, with increasing duration of the 35 culture, the amount of specific TCR- and actin-RNA decreased much more slowly. The result of these cultivation investigations is that evidently contaminating telomerase-positive nontumor cells have died as early as between day 0 and day 1.

Furthermore, under the RT-PCR conditions described with differing amounts of telomerase-positive tumor cells, the catalytic subunit of human telomerase can be detected in up to 10 cells.

5 Since, in contrast to the TRAP assay, highly purified RNA is used for amplification in the reverse transcriptase polymerase chain reaction (RT-PCR) method used according to the invention, an inhibition of Taq polymerase can be substantially excluded. In addition, 10 for the RT-PCR method described, a sensitivity for the detection of the RNA component (hTR) and the catalytic subunit (hTRT) of telomerase of about 1 cell per RT-PCR mixture was demonstrated. Thus, the use of the RT-PCR method described offers a comparable or better 15 sensitivity for the detection of telomerase-active tumor cells. Additionally, it was shown that the detection of hTR and hTRT expression correlates with the catalytic activity of telomerase (K. Yashima et al., J. Clin. Pathol. (1997), 50, 110-7).

Claims

1. Method for the quantification of tumor cells in a body fluid, characterized in that

5 (a) the sample to be investigated is subjected to a method for concentrating or depleting tumor cells and

(b) a reaction is carried out, on the concentrated or depleted tumor cells, in which the mRNA coding for the catalytic subunit of telomerase is specifically amplified, and

10 (c) the amount of amplified nucleic acid is determined quantitatively.

2. Method according to Claim 1, characterized in that a reverse transcription reaction in which the mRNA contained in the sample is transcribed into cDNA is carried out before the amplification reaction with the sample to be investigated.

15 3. Method according to Claims 1 or 2, characterized in that a DNase reaction is carried out with the sample to be investigated before the transcription of the mRNA into cDNA.

20 4. Method according to any of Claims 1 - 3, characterized in that the sample to be investigated is purified, preferably by an ion exchange chromatography, in particular on silica gel.

25 5. Method according to any of Claims 1 - 4, characterized in that, for quantitative determination of the telomerase-coding nucleic acid, the amplification products are labeled even during amplification and the amplification kinetics are measured continuously even during the amplification process.

30 6. Method according to Claim 5, characterized in that a probe which is specific for the amplification products, and which emits a characteristic signal proportional to the products amplified per synthesis cycle, is present during amplification.

35 7. Method according to any of Claims 1 - 4, characterized in that, for quantitative determination

of the telomerase-encoding nucleic acid, at least one, preferably three, standard nucleic acids are coamplified and are added in different concentrations to the sample to be investigated.

5 8. Method according to any of Claims 1 - 7, characterized in that the amplification product is quantified either directly or via a label, preferably via a radioactive label, a biotin label, a fluorescent label or an electrochemoluminescent label.

10 9. Method according to any of Claims 1 - 7, characterized in that the amplification product is detected via a hybridization with a labeled oligonucleotide, where the label is preferably a radioactive label, a biotin label, a fluorescent label 15 or an electrochemoluminescent label.

10. Method according to any of Claims 7 - 9, characterized in that, to quantify the telomerase-encoding nucleic acid to be determined, the amount of coamplified nucleic acid or nucleic acids is compared 20 with the amount of telomerase-encoding nucleic acid.

11. Method according to any of Claims 1 - 10, characterized in that the sample to be investigated is peripheral blood, and in that a reaction is carried out with the sample to be investigated as positive control, 25 in which a nucleic acid which occurs in peripheral blood, preferably the mRNA coding for β -globin, glyceraldehyde-phosphate dehydrogenase, β -actin or the T-cell receptor, is specifically amplified and detected.

30 12. Method according to Claim 1 or any of Claims 3 - 11, characterized in that, as negative controls, no reverse transcription reaction is carried out before the amplification reaction with the sample to be investigated and/or water is employed in place of the 35 body fluid.

13. Method according to any of Claims 1 - 12, characterized in that the following oligonucleotide primers are used for the amplification:

5' CTACCGGAAG AGTGTCTGGA GCAAGTTGCA AAGC 3' (hTRT1)

and/or

5' GGCATACCGA CGCACGCAGT ACGTGTTCTG 3' (hTRT2),

5 where hTRT1 and/or hTRT2 comprises where appropriate a promoter sequence for an RNA polymerase.

14. Method according to any of Claims 1 - 13, characterized in that a DNA polymerase or an RNA polymerase is used for the amplification.

10 15. Method according to any of Claims 1 - 14, characterized in that, in the case of amplification with DNA polymerase, the polymerase chain reaction (PCR) is carried out and, in the case of amplification with RNA polymerase, the isothermal nucleic acid 15 sequence-based amplification (NASBA) is carried out.

16. Method according to any of Claims 1 - 15, characterized in that the sample to be investigated is blood, and in that the blood sample to be investigated is depleted in stem cells and/or activated immune 20 cells, preferably by immunoabsorption.

17. Method according to any of Claims 1 - 16, characterized in that the sample to be investigated is blood, and the tumor cells from the blood sample to be investigated are concentrated, preferably by 25 immunoabsorption.

18. Method according to any of Claims 1 - 17, characterized in that the cells contained in the sample are cultivated under conditions which are unfavorable for telomerase-positive nontumor cells but favorable 30 for the tumor cells present.

19. Method according to Claim 18, characterized in that the duration of the cultivation is such that nontumor cells die and tumor cells survive.

20. Method according to any of Claims 1 - 19, 35 where, for concentrating the tumor cells, a cell separation medium is covered with a layer of the body fluid and centrifuged, characterized in that the cell separation medium has a density in the range from 1.055 to < 1.070 g/ml.

21. Method according to Claim 20, characterized in that the cell separation medium has a density in the range from 1.060-1.067 g/ml and preferably of about 1.065 g/ml.

5 22. Method according to Claim 20 or 21, characterized in that the centrifugation is carried out at about $1000 \times g$ for about 30 minutes.

23. Method according to any of Claims 20 - 22, characterized in that the cell separation medium used
10 is Percoll or Ficoll.

24. Method according to any of Claims 20 - 23, characterized in that the body fluid is, prior to being applied as a covering layer, admixed with one or more substances which prevent aggregation of platelets to
15 tumor cells, and/or the body fluid is, prior to being applied as a covering layer, freed of substances which promote aggregation of platelets to tumor cells.

25. Method according to any of Claims 20 - 24, characterized in that the body fluid is peripheral
20 blood.

26. Method according to Claim 25, characterized in that the peripheral blood is drawn in an anticoagulant substance and, prior to covering the cell separation medium, diluted with a diluent, preferably in a ratio
25 of about 1:1.

27. Method according to Claim 25 or 26, characterized in that the peripheral blood is venous or arterial blood.

28. Method according to any of Claims 20 - 24,
30 characterized in that the body fluid is selected from lymph, urine, exudates, transudates, spinal fluid, seminal fluid, saliva, fluids from natural or unnatural body cavities, bone marrow and dispersed body tissue.

29. Method according to any of Claims 20 - 28,
35 characterized in that the centrifugation vessel is, after centrifugation and before the tumor-cell-enriched interphase is removed, cooled intensively to prevent mixing of the cells in the different layers.

30. Method according to any of Claims 20 - 29, characterized in that the centrifugation is carried out in a vessel which is divided by a porous barrier, a filter or a sieve into an upper and a lower 5 compartment, where the cell suspension medium is initially charged in the lower compartment and the body fluid is introduced into the upper compartment.

31. Method according to Claim 30, characterized in that the porous barrier, the filter or the sieve have 10 [sic] a thickness of 1-10 mm, preferably about 5 mm.

32. Method according to Claim 30 or 31, characterized in that the porous barrier, the filter or the sieve have [sic] a pore size of 20-100 μm , preferably 20-30 μm .

15 33. Method according to any of Claims 30 - 32, characterized in that the porous barrier, the filter or the sieve are [sic] made of a hydrophobic material or coated with a hydrophobic material.

34. Method according to any of Claims 20 - 33, 20 characterized in that the cell separation medium contains a dye which makes the color of the cell separation medium distinguishable from that of the supernatant body fluid, thus simplifying the localization of the interphase.

25 35. Method according to any of Claims 1 - 34, characterized in that the sample to be investigated is blood, and in that there is an investigation in said method of, on the one hand, a venous blood sample and, on the other hand, an arterial blood sample, and the 30 results are compared with one another.

36. Method according to any of Claims 1 - 35, characterized in that the sample to be investigated is blood, and in that there is an investigation in said method of, on the one hand, a blood sample from the 35 finger pad and, on the other hand, a venous or arterial blood sample, and the results are compared with one another.

37. Method according to any of Claims 1 - 36, characterized in that the tumor cells are derived from

metastases, preferably micrometastases, of malignant tumors.

38. Method according to any of Claims 1 - 37, characterized in that the tumor cells are selected from 5 a group of cells of metastasizing tumors and/or neoplasms which are derived from a T-cell lymphoblastoma, T-cell leukemia cells, chronic myeloid leukemia cells, acute lymphatic leukemia cells, chronic lymphatic leukemia cells, teratocarcinoma, melanoma, 10 carcinoma of the lung, large intestine cancer, breast cancer, hepatocellular carcinoma, kidney tumor, adrenal tumor, prostate carcinoma, neuroblastoma, brain tumor, rhabdomyosarcoma, leiomyosarcoma and/or lymphoma.

39. Oligonucleotide primer with the sequence 15

5' CTACCGGAAG AGTGTCTGGA GCAAGTTGCA AAGC 3' (hTRT1)
and/or

5' GGCATACCGA CGCACGCAGT ACGTGTTCTG 3' (hTRT2),

20 where hTRT1 and/or hTRT2 may, if appropriate, additionally comprise a promoter sequence for an RNA polymerase.

40. Oligonucleotide probe with the sequence

25 5' CGTTCTGGCT CCCACGACGT AGTC 3' (hTRT o)

and/or the corresponding reverse complementary sequence thereof.

41. Kit for the quantification of tumor cells in a 30 body fluid, comprising:

(a) an oligonucleotide primer pair for specific amplification of telomerase-encoding nucleic acid.

42. Kit according to Claim 41, characterized in that the oligonucleotide primer pair specified in (a) 35 has the following sequences:

5' CTACCGGAAG AGTGTCTGGA GCAAGTTGCA AAGC 3' (hTRT1)

and/or

5' GGCATACCGA CGCACGCAGT ACGTGTTCTG 3' (hTRT2),

where hTRT1 and/or hTRT2 comprises where appropriate a promoter sequence for an RNA polymerase.

43. Kit according to either of Claims 41 or 42,
5 characterized in that it additionally comprises (b) a standard nucleic acid or standard nucleic acids for coamplification.

44. Kit according to any of Claims 41 - 43,
10 characterized in that it additionally comprises a labeled oligonucleotide for detecting the amplified nucleic acid of the sample to be determined and/or one or more labeled oligonucleotides for detecting the coamplified standard nucleic acid or standard nucleic acids, in particular an oligonucleotide with the
15 sequence:

5' CGTTCTGGCT CCCACGACGT AGTC 3' (hTRT o)

and/or the corresponding reverse complementary sequence
20 thereof.

45. Kit according to any of Claims 41 - 44,
characterized in that it additionally comprises a
reverse transcriptase, a DNA polymerase, preferably a
Taq polymerase, a DNase and/or suitable buffers and,
25 where appropriate, labeled nucleotides and, where
appropriate, means suitable for the depletion of stem
cells and/or activated immune cells and/or for the
concentration of tumor cells.

46. Kit according to any of Claims 41 - 45,
30 characterized in that it additionally comprises a
reverse transcriptase, an RNA polymerase, preferably a
T7 RNA polymerase, an RNase H, a DNase and/or suitable
buffers and, where appropriate, labeled nucleotides
and, where appropriate, means suitable for the
35 depletion of stem cells and/or activated immune cells
and/or for the concentration of tumor cells.

47. Kit according to any of Claims 41 - 46,
characterized in that it additionally comprises a cell
separation medium having a density in the range of from

1.055 to < 1.070 g/ml and, if appropriate, a centrifugation vessel.

48. Kit according to Claim 47, characterized in that the cell separation medium has a density in the 5 range of from 1.060 to 1.067 g/ml and preferably of about 1.065 g/ml.

49. Kit according to either of Claims 47 or 48, characterized in that the centrifugation vessel has a porous barrier, a filter or a sieve of a thickness of 10 1-10 mm, preferably of about 5 mm, which divide [sic] the centrifugation vessel into an upper and a lower compartment.

50. Kit according to Claim 49, characterized in that the porous barrier, the filter or the sieve have 15 [sic] a pore size of 20-100 μm , preferably 20-30 μm .

51. Kit according to Claim 49 or 50, characterized in that the cell separation medium is in the lower compartment of the centrifugation vessel.

Abstract

Method for the quantitative determination of tumor cells in a body fluid and test kits suitable therefor

A method for the quantification of tumor cells in a body fluid is disclosed and entails first subjecting the sample to be investigated to a method for concentrating or depleting tumor cells and carrying out a reaction on the concentrated or depleted tumor cells in which the mRNA coding for the catalytic subunit of the telomerase is specifically amplified, and then the amount of amplified nucleic acid is determined quantitatively, as are test kits suitable therefor.

09/601645

- 49 -

1	GCAGCGCTGC	GTCCTGCTGC	GCACGTGGGA	AGCCCTGGCC	CCGGCCACCC	CCGCATGCC
61	GCGCGCTCCC	CGCTGCCGAG	CCGTGCGCTC	CCTGCTGCGC	AGCCACTACC	GCGAGGTGCT
121	GCCGCTGGCC	ACGTTCTGTC	GGCGCCTGGG	GCCCCAGGGC	TGGCGGCTGG	TGCAGCGCGG
181	GGACCCGGCG	GCTTCCGCG	CGCTGGTGGC	CCAGTGCCTG	GTGTGCGTGC	CCTGGGACGC
241	ACGGCCGCC	CCGCCGCC	CCTCCTCCG	CCAGGTGTCC	TGCCTGAAGG	AGCTGGTGGC
301	CCGAGTGTG	CAGAGGCTGT	GGAGGCGGG	CGCGAAGAAC	GTGCTGGCCT	TCGGCTTCGC
361	GCTGCTGGAC	GGGGCCCGCG	GGGGCCCCCC	CGAGGCCTTC	ACCACCAGCG	TGCGCAGCTA
421	CCTGCCAAC	ACGGTGACCG	ACGCACTGCG	GGGGAGCGGG	GCGTGGGGC	TGCTGCTGCG
481	CCGCGTGGG	GACGACGTGC	TGGTTCACCT	GCTGGCACGC	TGCGCGCTCT	TTGTGCTGGT
541	GGCTCCCAGC	TGCGCCTACC	AGGTGTCGGG	GCCGCCGCTG	TACCAAGCTCG	GCGCTGCCAC
601	TCAGGCCCCG	CCCCCGCCAC	ACGCTAGTGG	ACCCCGAAGG	CGTCTGGGAT	GCGAACGGGC
661	CTGGAACCA	AGCGTCAGGG	AGGCCGGGGT	CCCCCTGGGC	CTGCCAGCCCC	CGGGTGCAGAG
721	GAGGCGCGGG	GGCAGTGCCA	GGCGAAGTCT	GCCGTTGCC	AAGAGGCCA	GGCGTGGCGC
781	TGCCCCCTGAG	CCGGAGCGGA	CGCCCGTTGG	GCAGGGTCC	TGGGCCCCACC	CGGGCAGGAC
841	GCGTGGACCG	AGTGACCGTG	TTTCTGTGT	GGTGTACCT	GCCAGACCCG	CCGAAGAACG
901	CACCTCTTTG	GAGGGTGC	TCTCTGGCAC	GGGCCACTCC	CACCCATCCG	TGGGCCCCCA
961	GCACCAACGCG	GGCCCCCAT	CCACATCGCG	GCCACCACGT	CCCTGGGACA	CGCCTTGTCC
1021	CCCAGTGTAC	GCCGAGACCA	AGCACTTCCT	CTACTCCTCA	GGCGACAAGG	AGCAGCTGCG
1081	GCCCTCCCTC	CTACTCAGCT	CTCTGAGGCC	CAGCCTGACT	GGCGCTCGGA	GGCTCGTGGA
1141	GACCATCTT	CTGGGTTCCA	GGCCCTGGAT	GGCAGGGACT	CCCCCGCAGGT	TGCCCCCGCT
1201	GCCCCAGCGC	TACTGGCAA	TGCGGCCCCCT	GTTTCTGGAG	CTGCTTGGGA	ACCACGCGCA
1261	GTGCCCTTAC	GGGGTGTCTC	TCAAGACCGA	CTGCCCGCTG	CGAGCTGCGG	TCACCCCCAGC
1321	AGCCGGTGT	TGTGCCGGG	AGAAGCCCCA	GGGCTCTGTG	GGGGCCCCCG	AGGAGGAGGA
1381	CACAGACCCC	CGTCGCCTGG	TGCAGCTGCT	GGGCCAGCAC	AGCAGCCCC	GGCAGGTGTA
1441	CGGCTTCGTG	CGGGCCTGCC	TGCGCCGGCT	GGTGCCTCCCCA	GGCCTCTGGG	GTCAGGCGCA
1501	CAACGAACGC	CGCTTCTCA	GAACACCAA	GAAGTTCATC	TCCCTGGGGA	AGCATGCCAA
1561	GCTCTCGCTG	CAGGAGCTGA	CGTGGAAAGAT	GAGCGTGC	GACTGCGCTT	GGCTGCGCAG
1621	GAGCCCAGGG	GTGGCTGTG	TTCCGGCCGC	AGAGCACCCT	CTGCGTGAGG	AGATCCCTGGC
1681	CAAGTTCTG	CACTGGCTGA	TGAGTGTGTA	CGTCGTCAG	CTGCTCAGGT	CTTTCTTTA
1741	TGTACCGGAG	ACCACGTTTC	AAAAGAACAG	GCTCTTTTC	<u>TACCGGAAGA</u>	<u>GTGTCTGGAG</u>
1801	<u>CAAGTTGCAA</u>	<u>AGCATTGGAA</u>	<u>TCAGACAGCA</u>	<u>CTTGAAGAGG</u>	<u>GTGCAGCTGC</u>	<u>GGGAGCTGTC</u>
1861	GGAAAGCAGAG	GTCAGGCAGC	ATCGGGAAAGC	CAGGCCGCC	CTGCTGACGT	CCAGACTCCG
1921	CTTCATCCCC	AAAGCCTGACG	GGCTGCGGCC	GATTGTGAAAC	ATGGACTACG	<u>TCGTGGGAGC</u>
1981	<u>CAAGAACGTT</u>	<u>CGCAGAGAAA</u>	<u>AGAGGGCCGA</u>	<u>GCGTCTCACC</u>	<u>TCGAGGGTGA</u>	<u>AGGCACGTGTT</u>
2041	CAGCGTGTCTC	AACTACCGAGC	GGGCGCGGCC	CCCCGGCTC	CTGGCGCCT	CTGTGCTGGG
2101	CCTGGACGAT	ATCCACAGGG	CCTGGCGCAC	CTTCGTGCTG	CGTGTGCGGG	CCCAGGACCC
2161	GCCGCTGAG	CTGTACTTTG	TCAAGGTGG	TGTGACGGGC	GCGTACGACA	CCATCCCCCA
2221	GGACAGGCTC	ACGGAGGTCA	TCGCCAGCAT	CATCAAACCC	<u>CAGAACACGT</u>	<u>ACTGCGTGC</u>
2281	<u>TCGGTATGCC</u>	<u>GTGGTCCAGA</u>	<u>AGGCCGCCA</u>	<u>TGGGCACGTC</u>	<u>CGCAAGGCC</u>	<u>TCAAGAGCCA</u>
2341	CGTCTCTACC	TTGACAGACC	TCCAGCCGTA	CATCGACAG	TTCGTGGCTC	ACCTGCAGGA
2401	GACCAGCCCG	CTGAGGGATG	CCGTCGTCT	CGAGCAGAGC	TCCTCCCTGA	ATGAGGCCAG
2461	CAGTGGCCTC	TTCGACGTCT	TCCTACGCTT	CATGTGCCAC	CACGCCGTGC	GCATCAGGGG
2521	CAAGTCTTAC	GTCCAGTGC	AGGGGATCCC	GCAGGGCTCC	ATCCTCTCCA	CGCTGCTCTG
2581	CAGCCTGTGC	TACGGCGACA	TGGAGAACAA	GCTGTTGCG	GGGATTGCGC	GGGACGGGCT
2641	GCTCTCTGCT	TTGGTGGATG	ATTTCTTGT	GGTGACACCT	CACCTCACCC	ACGCGAAAAC
2701	CTTCCTCAGG	ACCCCTGGTC	GAGGTGTCCC	TGAGTATGGC	TGCGTGGTGA	ACTTGCGGAA
2761	GACAGTGGTG	AACTCCCTG	TAGAAGACGA	GGCCCTGGGT	GGCACGGCTT	TTGTTCAAGAT
2821	GCGGCCAAC	GGCCTTTTCC	CCTGGTGC	CCTGCTGCTG	GATAACCGGA	CCCTGGAGGT
2881	GCAGAGCGAC	TACTCCAGCT	ATGCCCGGAC	CTCCATCAGA	GCCAGTCTCA	CCTTCAACCG
2941	CGGCTTCAAG	GCTGGGAGGA	ACATGCGTCG	CAAACCTTT	GGGGTCTTG	GGCTGAAGTG
3001	TCACAGCCTG	TTTCTGGATT	TGCAGGTGAA	CAGCCTCCAG	ACGGTGTGCA	CCAACATCTA
3061	CAAGATCCTC	CTGCTGCAGG	CGTACAGGTT	TCACGCATGT	GTGCTGCAGC	TCCCATTCTA
3121	TCAGCAAGTT	TGGAAGAAC	CCACATT	CCTGCGCTC	ATCTCTGACA	CGGCCTCCCT
3181	CTGCTACTCC	ATCCTGAAAG	CCAAGAACGC	AGGGATGTG	CTGGGGGCCA	AGGGCGCCGC
3241	CGGCCCTCTG	CCCTCCGAGG	CCGTGCAGTG	GCTGTGCCAC	CAAGCATTCC	TGCTCAAGCT
3301	GAATCGACAC	CGTGTACCT	ACGTGCCACT	CCTGGGGTCA	CTCAGGACAG	CCCAGACGCA

Fig. 1a

09/601645

- 50 -


3361 GCTGAGTCGG AAGCTCCGG GGACGACGCT GACTGCCCTG GAGGCCGCAG CCAACCCGGC
3421 ACTGCCCTCA GACTTCAAGA CCATCCTGGA CTGATGGCCA CCCGCCACA GCCAGGCCA
3481 GAGCAGACAC CAGCAGCCCT GTCACGCCGG GCTCTACGTC CCAGGGAGGG AGGGGCGGCC
3541 CACACCCAGG CCCGCACCGC TGGGAGTCTG AGGCCTGAGT GAGTGTGTTGG CCGAGGCCTG
3601 CATGTCCGGC TGAAGGCTGA GTGTCCGGCT GAGGCCTGAG CGAGTGTCCA GCCAAGGGCT
3661 GAGTGTCCAG CACACCTGCC GTCTTCACCT CCCCACAGGC TGGCGCTCGG CTCCACCCCA
3721 GGGCCAGCTT TTCCTCACCA GGAGGCCGGC TTCCACTCCC CACATAGGAA TAGTCCATCC
3781 CCAGATTCGC CATTGTCAC CCCTCGCCCT GCCCTCCCTT GCCTTCCACC CCCACCATCC
3841 AGGTGGAGAC CCTGAGAAGG ACCCTGGGAG CTCTGGGAAT TTGGAGTGAC CAAAGGTGTG
3901 CCCTGTACAC AGGCGAGGAC CCTGCACCTG GATGGGGGTC CCTGTGGTC AAATTGGGGG
3961 GAGGTGCTGT GGGAGTAAAA TACTGAATAT ATGAGTTTTT CAGTTTGAA AAAAA

Fig. 1b

09/601645

- 51 -

A



B




Fig. 2




Fig. 3

09/601645

- 53 -




Fig. 4

09/601645

- 54 -




Fig. 5

- 55 -

Catalytic subunit of human telomerase

<u>Name</u>	<u>Sequence (5`-3`)</u>
hTRT 1	CTACCGGAAGAGTGTCTGGAGCAAGTTGCAAAGC
hTRT 2	GGCATACCGACGCACGCAGTACGTGTTCTG
hTRT o	CGTTCTGGCTCCACGACGTAGTC

T-cell receptor:

<u>Name</u>	<u>Sequence (5`-3`)</u>
TCR 1	GAGGTCGCTGTGTTGAGCCATCAGAAG
TCR 2	GATCTCATAGAGGATGGTGGCAGACAG

β-actin:

<u>Name</u>	<u>Sequence (5`-3`)</u>
Act 1	GATGATGATATGCCCGCGCTCGTC
Act 2	CTCAAACATGATCTGGTCATCTTC

β-globin:

<u>Name</u>	<u>Sequence (5`-3`)</u>
Glob 1	ACCCAGAGGTTCTTGAGTC
Glob 2	TCTGATAGGCAGCCTGCACT

- 56 -

Whole blood/Ficoll-isolated PBMC

↓
RNA isolation using the 'whole blood protocol or standard methods such as phenol/chloroform or silica gel column

total RNA

↓
Amount of RNA corresponding to a certain vol. (e.g. 1 ml)
of whole blood

.....
buffer : 100 mM Tris/Cl,
pH 8.3

DNase- digest

30' / 37°C, 10' / 75°, 10" / 90°C
→ immediately on ice

50 mM KCl
5 mM MgCl₂
1 mM dNTP- mix
2.5 μM random hexamer
4U Rnase-free DNase
40U RNase inhibitor
in a volume of 36 μl

sample (18 μl) negative control (18 μl)

+ 50U MuLV RT
+ 40U Rnase inhibitor

+ 4 μl DEPC water

reverse transcriptase reaction

30' / 42°C, 5' / 99°

cDNA

(cDNA)

.....
buffer : 100 mM Tris/Cl,
pH 8.3

PCR- reaction¹⁾

50 mM KCl
2 mM MgCl₂
200 μM dNTP- mix
2.5U AmpliTaq DNA polymerase
300 μM per primer
in a volume of 25 μl

1) PCR-conditions :

15" / 97°C (15" / 97°C, 30" / 70°C, -0.5°C/cycle, 30" / 72°C) x 10
(15" / 94°C, 30" / 65°C, -0.5°C/cycle, 30" / 72°C) x 20
(15" / 94°C, 30" / 50°C, 30" (ext. 15" / cycle) / 72°C) x 10
7' / 72°C

Fig. 7

09/601645

- 57 -





Fig. 8



Mamma carcinoma (MD MB-435s)




Fig. 9

09/601645

- 59a -




Fig. 10

09/601645

- 59b -




Fig. 10

09/601645

526 Rec'd PCT/PTO 04 AUG 2000

SEQUENCE LISTING

<110> Dr. Dr. Michael Dahm

<120> Method for the quantitative determination of
tumor cells in a body fluid and test kits suitable
therefor

<130>

<140> PCT/EP99/00716

<141> 1999-02-03

<150> DE 198 04 372.4

<151> 1998-02-04

<160> 10

<170> PADAT Sequenzmodul, Version 1.0

<210> 1
<211> 34
<212> DNA
<213> Homo sapiens
<220>
<223>
<400> 1

ctaccggaag agtgtctgga gcaagttgca aagc

34

<210> 2
<211> 30
<212> DNA
<213> Homo sapiens
<220>
<223>
<400> 2

ggcataccga cgcacgcagt acgtgttctg

30

<210> 3
<211> 20
<212> DNA
<213> Homo sapiens
<220>
<223>
<400> 3

acccagaggt tctttgagtc

20

<210> 4
<211> 20
<212> DNA
<213> Homo sapiens
<220>
<223>
<400> 4

tctgataggc agcctgcact 20

<210> 5
<211> 24
<212> DNA
<213> Homo sapiens
<220>
<223>
<400> 5

gatgatgata tcgcccgcgt cgtc 24

<210> 6
<211> 25
<212> DNA
<213> Homo sapiens
<220>
<223>
<400> 6

ctcaaacatg atctgggtca tcttc 25

09545655 09545656
<210> 7
<211> 28
<212> DNA
<213> Homo sapiens
<220>
<223>
<400> 7

gaggtcgctg tgttttagcc atcagaag

28

<210> 8
<211> 27
<212> DNA
<213> Homo sapiens
<220>
<223>
<400> 8

gatctcatag aggatggtgg cagacag

27

<210> 9
<211> 24
<212> DNA
<213> Homo sapiens
<220>
<223>
<400> 9

cgttctggct cccacgacgt agtc

24

<210> 10
<211> 4015
<212> DNA
<213> Homo sapiens
<220>
<223>
<400> 10

gcagcgctgc gtcctgctgc gcacgtggga agccctggcc ccggccaccc cccgcgtgcc 60
gcccgcgtccc cgctgcccggag ccgtcgccgtc cctgctgcgc agccactacc gcgagggtgt 120
gcccgcgtggcc acgttcgtgc ggccgcctggg gccccagggc tggccggctgg tgcagcgcgg 180
ggaccggcgg gtttccggcg cgctggtggc ccagtgcctg gtgtgcgtgc cctgggacgc 240
acggccggccc cccggccggccc ccttccttcgg ccaggtgtcc tgcctgaagg agctgggtggc 300
ccgagtgctg cagaggctgt gcgagcgcgg cgcaagaac gtgcgtggct tggcttcgc 360
gtgcgtggac gggggccggcg gggggccccc cggggccttc accaccagcg tgccgcagcta 420
cctgcaccaac acggtgaccg acgcactgcg ggggagcggg gctgtggggc tgctgcgtcg 480
ccgcgtggc gacgacgtgc tggttcacct gctggcacgc tgccgcgtct ttgtgcgtgt 540
ggctcccagc tgccgcctacc aggtgtgcgg gcccgcgtg taccagctcg gcgctgcac 600
tcaggccccgg cccccggccac acgctagtgg accccgaagg cgtctggat gcaacgggc 660
ctggaaaccat agcgtcaggg aggccggggt cccccctggc ctggccagccc cgggtgcgag 720
gaggcgcggg ggcagtgcga gccaaggatct gcccgttgcgg aagaggccca ggcgtggcgc 780
tgccgcctgag cccggagcggg ccccccgtgg gcaagggttcc tggggccacc cggggcaggac 840
gcgtggaccg agtgcaccgtg gtttctgtgt ggtgtcacct gccagaccgg ccgaagaagc 900
caccttttgc gagggtgcgc tctctggcac gcccactcc caccatccg tggggcccca 960
gcaccacgcg gccccccat ccacatgcg gcccaccacgt cccctggaca ccccttgcc 1020
cccggtgtac gcccggagacca agcacttcct ctactcctca ggcgacaagg agcagctgcg 1080
gccccttc ctactcagct ctctggggcc caccctgtact ggcgcgtcgga ggctcggtgg 1140
gaccatcttt ctgggttcca ggcctggat gcccggact ccccccgcgtt tgccccgcct 1200
gccccagcgc tactggcaaa tgcggccctt gtttctggag ctgcgtggga accacgcgc 1260
gtgccttac ggggtgcctcc tcaagacgcg ctgccttcgt cgagctgcgg tcacccacgc 1320
agccgggtgtc tgtgcggccggg agaagccccca gggctctgtg gcccggccgg aggaggagga 1380
cacagacccc cgtcgccctgg tgcagctgtc cccgcac gcaaggccctt ggcagggtgt 1440
ccgcgttcgtg cggccctggc tgcgcgggt ggtgcggccca ggcctctggg gctccaggca 1500
caacgaacgc cgccttcctca ggaacacccaa gaagttcata tccctgggg agcacgc 1560
gctctcgctg caggagctga cgtgaaagat gaggcgtgcgg gactgcgtt ggctgcgcag 1620
gagcccaagg gttggctgtg ttccggccgc agagcaccgt ctgcgtgagg agatccctggc 1680

caagttcctg cactggctga tgagtgtgta cgtcgctcgag ctgctcaggt ctttctttta 1740
tgtcacggag accacgttcc aaaagaacag gcttttttc taccggaaga gtgtctggag 1800
caagttgcaa agcattggaa tcagacagca cttgaagagg gtgcagctgc gggagctg 1860
ggaagcagag gtcaggcagc atcgggaagc caggcccgcctc ctgctgacgt ccagactccg 1920
cttcatcccc aagcctgacg ggctgcccggcc gattgtgaac atggactacg tcgtgggagc 1980
cagaacgttc cgcaagagaaa agagggccga gctgttcacc tcgagggtga aggcactgtt 2040
cagcgtgctc aactacgagc gggcgccggcg ccccgccctc ctggcgccct ctgtgttggg 2100
cctggacgat atccacaggg cctggcgac ctctgtgtg cgtgtgcggg cccaggaccc 2160
gcccgcctgag ctgtactttt tcaaggtgga tgtgacgggc gcgtacgaca ccatccccca 2220
ggacaggctc acggaggctca tcgccagcat catcaaacc 2280
cagaacacgt actgcgtg 2280
tcggtatgcc gtggtccaga agggccccc tgggcacgtc cgcaaggcct tcaagagcca 2340
cgtctctacc ttgacagacc tccagccgta catgcacag ttcgtggctc acctgcagga 2400
gaccagcccg ctgagggatg ccgtcgcat cgacgagage tcctccctga atgaggccag 2460
cagtggccctc ttgcacgtct tcctacgctt catgtgccac caccggcgtgc gcatcagggg 2520
caagtccctac gtccagtgcc aggggatccc gcagggtctcc atccctctcca cgctgtctg 2580
cagcctgtgc tacggcgaca tggagaacaa gctgtttgcg gggattccgc gggacgggct 2640
gctcctgcgt ttgggtggatg atttcttggat ggtgacaccc caccctcaccc acgcgaaaac 2700
cttcctcagg accttggccgaggtgtccc tgagtatggc tgcgtggta acttgcggaa 2760
gacagtggtg aacttccctg tagaagacgaa ggcctgggt ggcacggctt ttgttcagat 2820
gccccccac ggcctattcc cctggcgccg cctgtgtctg gatacccgaa ccctggaggt 2880
gcagagcgac tactccagct atgcccggac ctccatcaga gccagtcac cccatccac 2940
cggcttcaag gctgggagga acatgcgtcg caaactctt ggggtcttcg ggctgaagt 3000
tcacagccctg ttctggatt tgcaggtgaa cagcctccag acgggtgtgca ccaacatcta 3060
caagatccctc ctgtgcagg cgtacaggtt tcacgcacgt gtgcgtcagc tcccttccat 3120
tcagcaagtt tggagaacc ccacattttt cctgcgcgtc atctctgaca cggccctccct 3180
ctgtactcc atctgaaag ccaagaacgc agggatgtcg ctggggccca agggcgccgc 3240
cgccctctg ccctccgagg ccgtgcagtg gctgtgcaccc caagcattcc tgctcaagct 3300
gactcgacac cgtgtcacct acgtccact cttgggtca ctcaggacag cccagacgca 3360
gctgagtcgg aagctcccg 3420
actgcctca gacttcaaga ccattctggaa ctgatggcca ccccccaca gccaggccga 3480
gagcagacac cagcagccct gtcacccgg gctctacgtc ccagggaggg aggggcggcc 3540
cacacccagg cccgcacccgc tgggagtcgtc aggcctgagt gagtgtttgg cccaggccctg 3600
catgtccggc tgaaggctga gtgtccggct gaggcctgag cgagtgtcca gccaagggt 3660
gagtgtccag cacacctgccc gtcttcactt cccacagac tggcgctcg 3720
ggccagctt ttccctcacca ggagccggc ttccactccc cacataggaa tagtccatcc 3780
ccagattcgc cattgttcac ccctcgccct gccccttgcctt gccttccacc cccaccatcc 3840
aggtggagac cctgagaagg accctggag ctctggaaat ttggagtgac caaagggttg 3900

ccctgtacac aggcgaggac cctgcacctg gatgggggtc cctgtgggtc aaattgggg 3960
gaggtgctgt gggagtaaaa tactgaatat atgagttt cagtttgaa aaaaa 4015

APPLICATION FOR UNITED STATES LETTERS PATENT

DECLARATION and POWER OF ATTORNEY

As below named inventors, we hereby declare that:

Our residence, post office address and citizenship are as stated below next to our name,

We believe we are the original, first and joint inventors of the subject matter which is claimed and for which a patent is sought on the invention entitled

"METHOD FOR QUANTITATIVELY ANALYZING TUMOR CELLS IN A BODY FLUID AND TEST KITS SUITED THEREFOR"

the specification of which

(check one) is attached hereto.

was filed on February 3, 1999 as Application Serial No. WO 99/40221 and amended in a Preliminary Amendment filed herewith.

We hereby state that we have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

We acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56.

We hereby claim foreign priority benefits under Title 35, United States Code, § 119 of any foreign application(s) for patent or inventor's certificate listed below or § 365 (a) of any PCT international application that designated at least one country other than the United States of America, listed below, and we have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)

Priority Claimed

198 04 372.4	Germany	4/February/1998	<input checked="" type="checkbox"/>	<input type="checkbox"/>
Number	Country	Day/Month/Year filed	yes	no

We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereof.

We hereby appoint the following attorneys and agents, with full power of substitution and revocation, to prosecute this application and to transact all business in the United States Patent & Trademark Office connected therewith and request that all correspondence and telephone calls in respect to this application be directed to Stephanie Seidman, HELLER EHRMAN WHITE & McAULIFFE, 4250 Executive Square, 7th Floor, La Jolla, California 92037-9103:

Attorney	Reg. No.
Stephanie Seidman	<u>33,779</u>
Paula K. Schoeneck	<u>39,362</u>
Barry S. Wilson	<u>39,431</u>

③ Address for correspondence: Stephanie Seidman
HELLER EHRMAN WHITE & McAULIFFE
4250 Executive Square
7th Floor
La Jolla, CA 92037-9103

1-00 Full name of joint inventor: Dr Dr Michael W. DAHM

Inventor's signature: Michael Dahm


Date: 16.06.1990

Residence: Gleimstrasse 2, D-81677 München DEX


Post Office Address:

Citizenship: Germany

20
Full name of joint inventor: Dr Robert C. PHELPS

Inventor's signature: 

Date: 16.06.2000

Residence:  DOHLENWEG 6
85757 KARLSFELD

DE

Post Office Address: 

Citizenship:  UFA

300
Full name of joint inventor: Dr Carsten BROCKMEYER

Inventor's signature: C. Brockmeyer

Date:

Residence: Thanner Str. 35a ~~Fellerer Strasse 2,~~ Thanner Str. 35a
D-83607 Holzkirchen ~~D-85354 Freising~~ 83607 Holzkirchen
DEX

Post Office Address:

Citizenship: Germany